Mutant phosphoenolpyruvate carboxylase, its gene, and production method of amino acid

Abstract

A phosphoenolpyruvate carboxylase gene, which has mutation such as mutation to replace 625th glutamic acid from the N-terminus of phosphoenolpyruvate carboxylase with lysine, mutation to replace 438th arginine from the N-terminus with cysteine and the like, is introduced into Escherichia coli or coryneform bacteria, so as to produce a phosphoenolpyruvate carboxylase which is not substantially inhibited by aspartic acid, thereby amino acid is efficiently produced.

Description

TECHNICAL FIELD

The present invention relates to a mutant phosphoenolpyruvate carboxylase, a gene coding for it, and a production method of an amino acid, and in particular relates to a gene having mutation to desensitize feedback inhibition by aspartic acid, and utilization thereof.

BACKGROUND ART

Phosphoenolpyruvate carboxylase is an enzyme which is found in almost all bacteria and all plants. The role of this enzyme resides in biosynthesis of aspartic acid and glutamic acid, and supply of C4 dicarboxylic acid to the citric acid cycle for maintaining its turnover. However, in the fermentative production of an amino acid using a microorganisms, there have been few reports on effects of this enzyme has not been made clear (Atsushi Yokota and Isamu Shiio, Agric. Biol. Chem., 52, 455-463 (1988), Josef Cremer et al., Appl. Environ. Microbiol., 57, 1746-1752 (1991), Petra, G. Peters-Weintisch, FEMS Microbial. Letters, 112, 269-274 (1993)).

By the way, the amino acid is a compound which universally exists in cells as components of proteins, however, for the sake of economic energy metabolism and substance metabolism, its production is strictly controlled. This control is principally feedback control, in which the final product of a metabolic pathway inhibits the activity of an enzyme which catalyzes the earlier step of the pathway. Phosphoenolpyruvate carboxylase also undergoes various regulations in expression of its activity.

For example, in the case of phosphoenolpyruvate carboxylase of microorganisms belonging to the genus Corynebacterium or the genus Escherichia, the activity is inhibited by aspartic acid. Therefore, the aforementioned amino acid biosynthesis, in which phosphoenolpyruvate carboxylase participates, is also inhibited by aspartic acid.

In the prior art, various techniques have been developed for efficient production in amino acid fermentation, and fermentative production has been carried out for leucine, isoleucine, tryptophan, phenylalanine and the like by using mutant strains converted to be insensitive to feedback control. However, there has been known neither mutant phosphoenolpyruvate carboxylase converted to be insensitive to inhibition by aspartic acid, nor attempt to utilize it for fermentative production of amino acids of the aspartic acid family and the glutamic acid family.

On the other hand, ppc gene, which is a gene coding for phosphoenolpyruvate carboxylase of Escherichia coli, has been already cloned, and also determined for its nucleotide sequence (Fujita, N., Miwa, T., Ishijima, S., Izui, K. and Katsuki, H., J. Biochem., 95, 909-916 (1984)). However, there is no report of a mutant in which inhibition by aspartic acid is desensitized.

The present invention has been made from the aforementioned viewpoint, an object of which is to provide a mutant phosphoenolpyruvate carboxylase with substantially desensitized feedback inhibition by aspartic acid, a gene conding for it, and a utilization method thereof.

DISCLOSURE OF THE INVENTION

As a result of diligent investigation in order to achieve the aforementioned object, the present inventors have found that the inhibition by aspartic acid is substantially desensitized by replacing an amino acid at a specified site of phosphoenolpyruvate carboxylase of Escherichia coli with another amino acid, succeeded in obtaining a gene coding for such a mutant enzyme, and arrived at completion of the present invention.

Namely, the present invention lies in a mutant phosphoenolpyruvate carboxylase, which originates from a microorganism belonging to the genus Escherichia, and has mutation to desensitize feedback inhibition by aspartic acid, and a DNA sequence coding for the mutant phosphoenolpyruvate carboxylase.

The present invention further provides microorganisms belonging to the genus Escherichia or coryneform bacteria harboring the DNA fragment, and a method of producing an amino acid wherein any of these microorganisms is cultivated in a preferable medium, and the amino acid selected from L-lysine, L-threonine, L-methionine, L-isoleucine, L-glutamic acid, L-arginine and L-proline is separated from the medium.

Incidentally, in this specification, the DNA sequence coding for the mutant phosphoenolpyruvate carboxylase, or a DNA sequence containing a promoter in addition thereto is occasionally merely referred to as "DNA sequence of the present invention", "mutant gene" or "phosphoenolpyruvate carboxylase gene."

The present invention will be explained in detail hereinafter.

<1> Mutant Phosphoenolpyruvate Carboxylase

The mutant phosphoenolpyruvate carboxylase of the present invention (hereinafter simply referred to as "mutant enzyme") lies in the phosphoenolpyruvate carboxylase of the microorganism belonging to the genus Escherichia, which has mutation to desensitize the feedback inhibition by aspartic acid.

Such mutation may be any one provided that the aforementioned feedback inhibition is substantially desensitized without losing the enzyme activity of the phosphoenolpyruvate carboxylase, for which there may be exemplified mutation which, when a mutant phosphoenolpyruvate carboxylase having the mutation is allowed to exist in cells of a microorganism belonging to the genus Escherichia, gives the cells resistance to a compound having the following properties:

it exhibits a growth inhibitory action against a microorganism belonging to the genus Escherichia which produces a wild type phosphoenolpyruvate carboxylase; the aforementioned growth inhibitory action is recovered by existence of L-glutamic acid or L-aspartic acid; and it inhibits wild type phosphoenolpyruvic carboxylase activity. More concretely, there may be exemplified, as counted from the N-terminus of the phosphoenolpyruvate carboxylase: (1) mutation to replace 625th glutamic acid with lysine; (2) mutation to replace 222th arginine with histidine and 223th glutamic acid with lysine, respectively; (3) mutation to replace 288th serine with phenylalanine, 289th glutamic acid with lysine, 551th methionine with isoleucine and 804th glutamic acid with lysine, respectively; (4) mutation to replace 867th alanine with threonine; (5) mutation to replace 438th arginine with cysteine; and (6) mutation to replace 620th lysine with serine.

Incidentally, as the phosphoenolpyruvate carboxylase of the microorganism belonging to the genus Escherichia, an amino acid sequence, which is deduced from a phosphoenolpyruvate carboxylase gene of Escherichia coli (Fujita, N., Miwa, T., Ishijima, S., Izui, K. and Katsuki, H., J. Biochem., 95, 909-916 (1984)), is shown in SEQ ID NO:2 in the Sequence listing. In addition, an entire nucleotide sequence of a plasmid pT2, which contains the phosphoenolpyruvate carboxylase gene of Escherichia coli, is shown in SEQ ID NO:1 together with the amino acid sequence.

The aforementioned mutant enzymes are encoded by DNA sequences of the present invention described below, which are produced by expressing the DNA sequences in Escherichia coli and the like.

<2> DNA Sequence of the Present Invention and Microorganisms Harboring the Same

The DNA sequence of the present invention is DNA sequences coding for the aforementioned mutant enzymes, and has mutation to desensitize feedback inhibition of phosphoenolpyruvate carboxylase by aspartic acid in coding regions in DNA fragments coding for phosphoenolpyruvate carboxylase of the microorganism belonging to the genus Escherichia.

Concretely, there may be exemplified a DNA Sequence coding for the phosphoenolpyruvate carboxylase having the mutation of any one of the aforementioned (1) to (6), for example, with respect to the nucleotide sequence of SEQ ID NO:1, there may be exemplified a DNA sequence having any one of:

i) mutation to convert GAA of base Nos. 2109-2111 into AAA or AAG; ii) mutation to convert CGC of base Nos. 900-902 into CAT or CAC, and GAA of 903-905 into AAA or AAG, respectively; iii) mutation to convert TCT of base Nos. 1098-1100 into TTT or TTC, GAA of 1101-1103 into AAA or AAG, ATG of 1887-1889 into ATT, ATC or ATA, and GAA of 2646-2648 into AAA or AAG, respectively; iv) mutation to convert GCG of 2835-2837 into any one of ACT, ACC, ACA and ACG; and v) mutation to convert CGT of 1548-1550 into TGT or TGC; and vi) mutation to convert AAA of 2094-2096 into TCT, TCC, TCA or TCG.

Such a mutant gene is obtained such that a recombinant DNA, which is obtained by ligating a phosphoenolpyruvate carboxylase gene as a wild type enzyme gene or having another mutation with a vector DNA adaptable to a host, is subjected to a mutation treatment, to perform screening from transformants by the recombinant DNA. Alternatively, it is also acceptable that a microorganism which produces a wild type enzyme is subjected to a mutation treatment, a mutant strain which produces a mutant enzyme is created, and then a mutant gene is screened from the mutant strain. For the mutation treatment of the recombinant DNA, hydroxylamine and the like may be used. Further, when an microorganism itself is subjected to a mutation treatment, a drug or a method usually used for artificial mutation may be used.

Further, in accordance with methods such as the Overlapping Extension method (Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. K. and Pease, L. R., Gene, 77, 51-59 (1989)), the site specific mutation method (Kramer, W. and Frits, H. J., Meth. in Enzymol., 154, 350 (1987); Kunkel, T. A. et al., Meth. in Enzymol., 154, 367 (1987)) and the like, the aforementioned mutant gene can be also obtained by introducing mutation such as amino acid replacement, insertion, deletion and the like into a phosphoenolpyruvate carboxylase gene as a wild type enzyme gene or having another mutation. These methods are based on a principle that a non-mutated gene DNA is used as a template, and a synthetic DNA containing a mismatch at a mutation point is used as one of primers so as to synthesize complemental strands of the aforementioned gene DNA, thereby mutation is introduced. By using these methods, it is possible to cause intended mutation at an aimed site.

Alternatively, a sequence, which has restriction enzyme cleavage ends at both termini and includes both sides of a mutation point, is synthesized, and exchanged for a corresponding portion of a non-mutated gene, thereby mutation can be introduced (cassette mutation method).

The phosphoenolpyruvate carboxylase gene, which is the wild type enzyme gene or has another mutation to be used for introduction of mutation, may be any one provided that it is a gene coding for the phosphoenolpyruvate carboxylase of the microorganism belonging to the genus Escherichia, which is preferably determined for its base sequence and cloned. When it has not been cloned, a DNA fragment containing the gene can be amplified and isolated by using the PCR method and the like, followed by using a suitable vector to achieve cloning.

As the gene as described above, for example, there may be exemplified a gene of Escherichia coli having been cloned and determined for its base sequence (Fujita, N., Miwa, T., Ishijima, S., Izui, K. and Katsuki, H., J. Biochem., 95, 909-916 (1984)). The sequence in the coding region of this gene is as shown in SEQ ID NO: 1 (base Nos. 237-2888).

Screening of a host harboring the mutant gene can be performed by using an analog compound of aspartic acid. The analog compound preferably has the following properties. Namely, it exhibits a growth inhibitory action against a microorganism belonging to the genus Escherichia which produces a wild type phosphoenolpyruvate carboxylase, the aforementioned growth inhibitory action is recovered by existence of L-glutamic acid or L-aspartic acid, and it inhibits wild type phosphoenolpyruvate carboxylase activity.

If a mutant strain beeing resistant to the analog compound mentioned above is selected from microorganism belonging to the genus Escherichia, for example, Escherichia coli HB101 producing wild type phosphoenolpyruvate carboxylase using inhibition of growth of the microorganism as an index, it is much likely to obtain a host microorganism which produces phosphoenolpyruvate carboxylase with desensitized feedback inhibition by aspartic acid.

It is proposed, as a general structure of an inhibitor of phosphoenolpyruvate carboxylase, that a C4 dicarboxylic acid structure is essentially provided. From such a viewpoint, various compounds were subjected to screening by the present inventors. Escherichia coli HB101 was cultivated in an LB medium, and transferred to M9 media (containing 20 .mu.g/ml of thiamine and 3 .mu.g/ml of each of Leu and Pro) containing any one of DL-2-amino-4-phosphonobutyric acid, bromosuccinic acid, meso-2,3-dibromosuccinic acid, 2,2-difluorosuccinic acid, 3-bromopyruvic acid, .alpha.-ketobutyric acid, .alpha.-ketoadipinic acid DL-threo-.beta.-hydroxyaspartic acids L-aspartic acid .beta.-metyl ester .alpha.-metyl-DL-aspartic acid, 2,3-diaminosuccinic acid or aspartic acid-.beta.-hydrazide, and absorbance of the medium was measured at 660 nm with the passage of time, thereby growth was monitored.

Further, when these compounds were present at their growth inhibitory concentrations, it was investigated whether or not the inhibition was recovered by addition of nucleic acids (each of uridine, adenosine: 10 mg/dl), glutamic acid or amino acids of the aspartic acid family (Asp: 0.025%, each of Met, Thr, Lys: 0.1%).

As a result, three compounds: 3-bromopyruvate (3 BP) (1), aspartate-.beta.-hydrazide (AHY) (2), and DL-threo-.beta.-hydroxyaspartate (.beta.HA) (3) were selected. ##STR1##

Growth inhibition of Escherichia coli by these analog compounds is shown in FIGS. 1-3. Further, growth recovery of Escherichia coli, in the case of addition of the aforementioned inhibition recovering substances alone or as a mixture of 2 species or 3 species, is shown in FIGS. 4-6. In addition, as a control, growth in the case of addition of the inhibition recovering substance in the absence of the inhibitory substance is shown in FIG. 7. Incidentally, in FIGS. 4-7, additives 1, 2 and 3 indicate nucleic acids, glutamic acid or amino acids of the aspartic acid family, respectively.

Further, inhibition of activity by the analog compound on phosphoenolpyruvate carboxylase was investigated. Crude enzyme was prepared from an Escherichia coli HB101 strain in accordance with a method described in The Journal of Biochemistry, Vol. 67, No. 4 (1970), and enzyme activity was measured in accordance with a method described in Eur. J. Biochem., 202, 797-803 (1991).

Escherichia coli HB101 cultivated in an LB medium was disrupted, and a suspension was centrifuged to obtain a supernatant which was used as a crude enzyme solution. Measurement of enzyme activity was performed by measuring decrease in absorbance at 340 nm while allowing acetyl-coenzyme A known to affect the activity to exist at a concentration of 0.1 mM in a measurement system containing 2 mM potassium phosphoenolpyruvate, 0.1 mM NADH, 0.1M Tris-acetate (pH 8.5), 1.5 U malate dehydrogenase and crude enzyme. Results are shown in FIG. 8.

According to the results as above, it is apparent that the aforementioned three compounds inhibit growth of Escherichia coli, this inhibition cannot be recovered by nucleic acids alone, but the inhibition can be recovered by addition of glutamic acid or amino acids of the aspartic acid family. Therefore, these analog compounds were postulated to be selective inhibitors of phosphoenolpyruvate carboxylase. As shown in Examples described below, by using these compounds, the present invention has succeeded in selection of an Escherichia coli which produces the mutant phosphoenolpyruvate carboxylase.

When a transformant having an aimed mutant enzyme gene is screened by using the aforementioned compounds, and a recombinant DNA is recovered, then the mutant enzyme gene is obtained. Alternatively, in the case of a mutation treatment of an microorganism itself, when a mutant strain having an aimed mutant enzyme gene is screened by using the aforementioned compounds, a DNA fragment containing the aimed mutant enzyme gene is isolated from the strain, and it is ligated with a suitable vector, then the mutant enzyme gene is obtained.

On the other hand, as a result of diligent investigation by the present inventors taking notice of importance of an arginine residue in an aspartate binding protein of Escherichia coli (Krikos, A., Mouth, N., Boyd, A. and Simon, M. I. Cell, 33, 615-622 (1983), Mowbray, S. L and Koshland, D. E. J. Biol. Chem., 264, 15638-15643 (1990), Milburn, M. V., Prive, G. G., Milligan, D. L., Scott, W. G., Yeh, J., Jancarik, J., Koshland, D. E. and Kim, S. H., Science, 254, 1342-1347 (1991)), it has been found that inhibition by aspartic acid is substantially desensitized by converting 438th arginine of phosphoenolpyruvate carboxylase into cysteine. In order to convert 438th arginine into cysteine, a codon of 438th arginine of a gene coding for phosphoenolpyruvate carboxylase may be converted into a codon of cysteine. For example, in SEQ ID NO:1, CGT of nucleotide numbers of 1548-1550 may be converted into TGT or TGC.

Further, the present inventors performed chemical modification of lysine residues of phosphoenolpyruvate carboxylase by using 2,4,6-trinitrobenzenesulfonic acid (TNBS) which is a compound to chemically modify lysine residues of a protein. During modification reaction, malic acid capable of serving as an inhibitor of phosphoenolpyruvate carboxylase was allowed to exist together. Namely, it was assumed that a lysine residue in the vicinity of a binding position of phosphoenolpyruvate carboxylase would be protected by bound malic acid and not be subjected to chemical modification. As a result, it was suggested that a 620th lysine residue was important for malic acid to bind phosphoenolpyruvate carboxylase, and it was found that the feedback inhibition by aspartic acid was desensitized while maintaining the enzyme activity of phosphoenolpyruvate carboxylase by converting the 620th lysine residue into a serine residue. In order to convert the 620th lysine residue into the serine residue, a codon of 620th lysine of the gene coding for phosphoenolpyruvate carboxylase may be converted into a codon of serine. For example, in SEQ ID NO:1, AAA having nucleotide numbers of 2094-2096 may be replaced with TCT, TCC, TCA, TCG, AGT or AGC.

In accordance with methods such as the Overlapping Extension method (Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. K. and Pease, L. R., Gene, 77, 51-59 (1989)), the site specific mutation method (Kramer, W. and Frits, H. J., Meth. in Enzymol., 154, 350 (1987); Kunkel, T. A. et al., Meth. in Enzymol., 154, 367 (1987)) and the like, conversion of the codon can be also achieved by introducing mutation such as amino acid replacement, insertion, deletion and the like into a phosphoenolpyruvate carboxylase gene as a wild type enzyme gene or having another mutation. These methods are based on a principle that a non-mutated gene DNA is used as a template, and a synthetic DNA containing a mismatch at a mutation point is used as one of primers so as to synthesize complemental strands of the aforementioned gene DNA, thereby mutation is introduced. By using these methods, it is possible to cause intended mutation at an aimed site.

Alternatively, a sequence, which has restriction enzyme cleavage ends at both termini and contains both sides of a mutation point, is synthesized, and exchanged for a corresponding portion of a non-mutated gene, thereby mutation can be introduced (cassette mutation method).

The DNA fragment coding for the phosphoenolpyruvate carboxylase with mutation introduced as described above is expressed by using a suitable host-vector system, thereby it is possible to produce a mutant enzyme. Alternatively, even by performing transformation by integrating the DNA fragment of the present invention into a host chromosomal DNA, an aimed mutant enzyme can be produced.

As the host, there may be exemplified microorganisms belonging to the genus Escherichia, for example, Escherichia coli, coryneform bacteria and the like. The coryneform bacteria include bacteria belonging to the genus Corynebacterium, bacteria belonging to the genus Brevibacterium having been hitherto classified into the genus Brevibacterium but being united as bacteria belonging to the genus Corynebacterium at present, and bacteria belonging to the genus Brevibacterium closely related to bacteria belonging to the genus Corynebacterium. Incidentally, hosts which are preferable for amino acid production will be described below.

On the other hand, as the vector DNA, a plasmid vector is preferable, and those capable of self-replication in a host cell are preferable. When the host is Escherichia coli, for example, pUC19, pUC18, pBR322, pHSG299, pHSG399, RSF1010 and the like are exemplified. Alternatively, a vector of phage DNA can be also utilized.

Further, when the host is the coryneform bacteria, vectors which can be used and hosts which harbor them are exemplified below. Incidentally, deposition numbers of international depositories are shown in parentheses.

pAJ655 Escherichia coli AJ11882 (FERM BP-136) Corynebacterium glutamicum SR8201 (ATCC 39135) pAJ1844 Escherichia coli AJ11883 (FERM BP-137) Corvnebacterium glutamicum SR8202 (ATCC 39136) pAJ611 Escherichia coli AJ11884 (FERM BP-138) pAJ3148 Corynebacterium glutamicum SR8203 (ATCC 39137) pAJ440 Bacillus subtilis AJ11901 (FERM BP-140)

These vectors may be obtained from the deposited microorganisms as follows. Cells collected at the logarithmic growth phase are subjected to bacteriolysis by using lysozyme and SDS, and centrifuged at 30000.times.g to obtain a supernatant solution from a lysate, to which polyethylene glycol is added to perform separation and purification of the vectors by means of cesium chloride-ethidium bromide equilibrium density gradient centrifugation.

In order to transform Escherichia coli with a recombinant vector obtained by inserting the DNA sequence of the present invention into the aforementioned vector, it is possible to use a method usually used for transformation of Escherichia coli, such as a method in which cells are treated with calcium chloride to enhance permeability of DNA (Mandel, M. and Higa, A., J. Mol. Biol., 53, 159 (1977)) and the like.

Further, as a method for transforming the coryneform bacteria, there is the aforementioned method in which cells are treated with calcium chloride, or a method in which incorporation is performed at a specified growth period in which cells can incorporate DNA (report in relation to Bacillus subtilis by Duncan, C. H. at al.). Further, incorporation into bacterial cells can be achieved by forming protoplasts or spheroplasts of DNA recipients which easily incorporate plasmid DNA. These are known for Bacillus subtilis, Actinomyces and yeast (Chang, S. et al., Molec. Gen. Genet., 168, 111 (1979), Bibb et al., Nature, 274, 398 (1978), Hinnen, A. et al., Proc. Natl. Acad. Sci. USA, 75 1929 (1978)). Additionally, a method for transforming coryneform bacteria is disclosed in Japanese Patent Laid-open No. 2-207791.

In order to express the DNA sequence of the present invention in the aforementioned hosts, a promoter such as lac, trp, PL and the like which efficiently works in microorganisms may be used, or when the DNA sequence of the present invention contains a promoter of the phosphoenolpyruvate carboxylase gene, it may be used as it is. Alternatively, when the coryneform bacterium is used as the host, it is also possible to use a known trp promoter originating from a bacterium belonging to the genus Brevibacterium (Japanese Patent Laid-open No. 62-244382) and the like.

Further, as described above, it is acceptable that the DNA sequence of the present invention is inserted into the vector DNA capable of self-replication and introduced into the host to allow the host to harbor it as a plasmid, and it is also acceptable that the DNA sequence of the present invention is integrated into a chromosome of an microorganism by means of a method using transposon (Berg, D. E. and Berg, C. M., Bio/Technol., 1, 417 (1983)), Mu phage (Japanese Patent Laid-open No. 2-109985) or homologous recombination (Experiments in Molecular Genetics, Cold Spring Harbor Lab. (1972)). In addition, in order to integrate the DNA of the present invention into the coryneform bacteria, it is possible to utilize a temperature-sensitive plasmid disclosed in Japanese Patent Laid-open No. 5-7491.

When the microorganism transformed with the DNA sequence of the present invention as described above is cultivated, and this DNA sequence is expressed, then a mutant enzyme is obtained. It becomes apparent, by measuring the activity by adding aspartic acid to an enzyme reaction system, whether or not the mutant enzyme thus obtained has desensitized feedback inhibition by aspartic acid. It is possible for the measurement of the enzyme activity to use a spectrometric method (Yoshinage, T., Izui, K. and Katsuki, H., J. Biochem., 68, 747-750 (1970)) and the like.

Further, the DNA sequence of the present invention codes for the mutant enzyme in which feedback inhibition by aspartic acid is desensitized, so that the microorganism harboring this DNA sequence can be utilized for efficient fermentative production of amino acids of the aspartic acid family and the glutamic acid family as described below.

Escherichia coli AJ12907, AJ12908, AJ12909 and AJ12910 harboring the mutant enzyme genes obtained in Examples described below are deposited in National Institute of Bioscience and Human Technology of Agency of Industrial Science and Technology (1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan; zip code 305) on Aug. 3, 1993 under the deposition numbers of FERM P-13774, FERM P-13775, FERM P-13776 and FERM P-13777, transferred from the original deposition to international deposition based on Budapest Treaty on Jul. 11, 1994 and has been deposited as deposition numbers of FERM BP-4734, FERM BP-4735, FERM BP-4736, FERM BP-4737, respectively in this order.

<3> Production Method of Amino Acids

Amino acids can be produced by cultivating the microorganism harboring the DNA sequence of the present invention in a preferable medium, and separating generated amino acids. As such amino acids, there may be exemplified L-lysine, L-threonine, L-methionine, L-isoleucine, L-glutamic acid, L-arginine and L-proline.

Preferable hosts into which the DNA sequence of the present invention is introduced to be used for production of each of the amino acids, and a cultivation method will be exemplified below.

(1) Hosts Preferable for the Amino Acid Production Method of the Present Invention

(i) Hosts preferable for L-lysine production

As the host to be used for L-lysine production according to the present invention, there may be exemplified bacteria belonging to the genus Escherichia, preferably L-lysine-producing Escherichia coli. Concretely, a mutant strain having resistance to a lysine analog can be exemplified. Such a lysine analog is those which inhibit growth of microorganisms belonging to the genus Escherichia, however, the suppression is totally or partially desensitized provided that L-lysine co-exits in the medium. For example, there are oxalysine, lysine hydroxamate, S-(2-aminoethyl)-cysteine (hereinafter abbreviated as "AEC"), .gamma.-methyllysine, .alpha.-chlorocaprolactam and the like. Mutant strains having resistance to these lysine analogs can be obtained by applying an ordinary artificial mutation treatment to microorganisms belonging to the genus Escherichia. Concretely, as a bacterial strain to be used for L-lysine production, there may be exemplified Escherichia coli AJ11442 (deposited as FERM P-5084, see lower-left column on page 471 in Japanese Patent Laid-open No. 56-18596).

On the other hand, various artificial mutant strains of coryneform bacteria which have been used as L-lysine-producing bacteria can be used for the present invention. Such artificial mutant strains are as follows: AEC resistant mutant strain; mutant strain which requires amino acid such as L-homoserine for its growth (Japanese Patent Publication Nos. 48-28078 and 56-6499); mutant strain which exhibits resistance to AEC and requires amino acid such as L-leucine, L-homoserine, L-proline, L-serine, L-arginine, L-alanine, L-valine and the like (U.S. Pat. Nos. 3,708,395 and 3,825,472); L-lysine-producing mutant strain which exhibits resistance to DL-.alpha.-amino-.epsilon.-caprolactam, .alpha.-amino-lauryllactam, quinoid and N-lauroylleucine; L-lysine-producing mutant strain which exhibits resistance to an inhibitor of oxaloacetate decarboxylase or respiratory system enzyme (Japanese Patent Laid-open Nos. 50-53588, 50-31093, 52-102498, 53-86089, 55-9783, 55-9759, 56-32995 and 56-39778, and Japanese Patent Publication Nos. 53-43591 and 53-1833); L-lysine-producing mutant strain which requires inositol or acetic acid (Japanese Patent Laid-open Nos. 55-9784 and 56-8692); L-lysine-producing mutant strain which exhibits sensitivity to fluoropyruvate or temperature not less than 34.degree. C. (Japanese Patent Laid-open Nos. 55-9783 and 53-86090); and mutant strain of Brevibacterium or Corynebacterium which exhibits resistance to ethylene glycol and produces L-lysine (see U.S. patent application Ser. No. 333455).

Followings are exemplified as concrete coryneform bacteria to be used for lysine production:

Brevibacterium lactofermentum AJ12031 (FERM-BP277), see page 525 in Japanese Patent Laid-open No. 60-62994;

Brevibacterium lactofermentum ATCC 39134, see lower-right column on page 473 in Japanese Patent Laid-open No. 60-62994;

Brevibacterium lactofermentum AJ3463 (FERM-P1987), see Japanese Patent Publication No. 51-34477.

In addition, wild strains of coryneform bacteria described below can be also used for the present invention in the same manner.

______________________________________Corynebacterium acetoacidophilum ATCC 13870Corynebacterium acetoglutamicum ATCC 15806Corynebacterium callunae ATCC 15991Corynebacterium glutamicum ATCC 13032 ATCC 13060(Brevibacterium divaricatum) ATCC 14020(Brevibacterium lactofermentum) ATCC 13869(Corynebacterium lilium) ATCC 15990Corynebacterium melassecola ATCC 17965Brevibacterium saccharolyticum ATCC 14066Brevibacterium immariophilum ATCC 14068Brevibacterium roseum ATCC 13825Brevibacterium flavum ATCC 13826Brevibacterium thiogenitalis ATCC 19240Microbacterium ammoniaphilum ATCC 15354______________________________________

(ii) Hosts preferable for L-threonine production

Escherichia coli B-3996 (RIA 1867), see Japanese Patent Laid-open No. 3-501682 (PCT); Escherichia coli AJ12349 (FERM-P9574), see upper-left column on page 887 in Japanese Patent Laid-open No. 2-458; Escherichia coli AJ12351 (FERM-P9576), see lower-right column on page 887 in Japanese Patent Laid-open No. 2-458; Escherichia coli AJ12352 (FERM P-9577), see upper-left column on page 888 in Japanese Patent Laid-open No. 2-458; Escherichia coli AJ11332 (FERM P-4898), see upper-left column on page 889 in Japanese Patent Laid-open No. 2-458; Escherichia coli AJ12350 (FERM P-9575), see upper-left column on page 889 in Japanese Patent Laid-open No. 2-458; Escherichia coli AJ12353 (FERM P-9578), see upper-right column on page 889 in Japanese Patent Laid-open No. 2-458; Escherichia coli AJ12358 (FERM P-9764), see upper-left column on page 890 in Japanese Patent Laid-open No. 2-458; Escherichia coli AJ12359 (FERM P-9765), see upper-left column on page 890 in Japanese Patent Laid-open No. 2-458;

Escherichia coli AJ11334 (FERM P-4900), see column 6 on page 201 in Japanese Patent Publication No. 1-29559;

Escherichia coli AJ11333 (FERM P-4899), see column 6 on page 201 in Japanese Patent Publication No. 1-29559; Escherichia coli AJ11335 (FERM P-4901), see column 7 on page 202 in Japanese Patent Publication No. 1-29559.

Following bacterial strains are exemplified as the coryneform bacteria:

Brevibacterium lactofermentum AJ11188 (FERM P4190), see upper-right column on page 473 in Japanese Patent Laid-open No. 60-87788; Corynebacterium plutamicum AJ11682 (FERM BP-118), see column 8 on page 230 in Japanese Patent Publication No. 2-31956; Brevibacterium flavum AJ11683 (FERM BP-119), see column 10 on page 231 in Japanese Patent Publication No. 2-31956.

(iii) Hosts preferable for L-methionine production

Following bacterial strains are exemplified for L-methionine production:

Escherichia coli AJ11457 (FERM P-5175), see upper-right column on page 552 in Japanese Patent Laid-open No. 56-35992; Escherichia coli AJ11458 (FERM P-5176), see upper-right column on page 552 in Japanese Patent Laid-open No. 56-35992; Escherichia coli AJ11459 (FERM P-5177), see upper-right column on page 552 in Japanese Patent Laid-open No. 56-35992; Escherichia coli AJ11539 (FERM P-5479), see lower-left column on page 435 in Japanese Patent Laid-open No. 56-144092; Escherichia coli AJ11540 (FERM P-5480), see lower-left column on page 435 in Japanese Patent Laid-open No. 56-144092; Escherichia coli AJ11541 (FERM P-5481), see lower-left column on page 435 in Japanese Patent Laid-open No. 56-144092; Escherichia coli AJ11542 (FERM P-5482), see lower-left column on page 435 in Japanese Patent Laid-open No. 56-144092.

(iv) Hosts preferable for L-aspartic acid production

Following bacterial strains are exemplified for L-aspartic acid production:

Brevibacterium flavum AJ3859 (FERM P-2799), see upper-left column on page 524 in Japanese Patent Laid-open No. 51-61689; Brevibacterium lactofermentum AJ3860 (FERM P-2800), see upper-left column on page 524 in Japanese Patent Laid-open No. 51-61689; Corynebacterium acetoacidophilum AJ3877 (FERM-P2803), see upper-left column on page 524 in Japanese Patent Laid-open No. 51-61689; Corynebacterium glutamicum AJ3876 (FERM P-2802), see upper-left column on page 524 in Japanese Patent Laid-open No. 51-61689.

(v) Hosts preferable for L-isoleucine production

Escherichia coli KX141 (VKPM-B4781) (see 45th paragraph in Japanese Patent Laid-open No. 4-33027) is exemplified as the bacteria belonging to the genus Escherichia, and Brevibacterium lactofermentum AJ12404 (FERM P-10141) (see lower-left column on page 603 in Japanese Patent Laid-open No. 2-42988) and Brevibacterium flavum AJ12405 (FERM P-10142) (see lower-left column on page 524 in Japanese Patent Laid-open No. 2-42988) are exemplified as the coryneform bacteria.

(vi) Hosts preferable for L-glutamic acid production

Following bacterial strains are exemplified as the bacteria belonging to the genus Escherichia:

Escherichia coli AJ12628 (FERM P-12380), see French Patent Publication No. 2 680 178 (1993); Escherichia coli AJ12624 (FERM P-12379), see French Patent Publication No. 2 680 178 (1993).

Following bacterial strains are exemplified as the coryneform bacteria:

Brevibacterium lactofermentum AJ12745 (FERM BP-2922), see lower-right column on page 561 in Japanese Patent Laid-open No. 3-49690; Brevibacterium lactofermentum AJ12746 (FERM BP-2923), see upper-left column on page 562 in Japanese Patent Laid-open No. 3-49690; Brevibacterium lactofermentum AJ12747 (FERM BP-2924), see upper-left column on page 562 in Japanese Patent Laid-open No. 3-49690; Brevibacterium lactofermentum AJ12748 (FERM BP-2925), see upper-left column on page 562 in Japanese Patent Laid-open No. 3-49690; Brevibacterium flavum ATCC 14067, see Table 1 on page 3 in Japanese Patent Laid-open No. 5-3793; Corynebacterium glutamicum ATCC 21492, see Table 1 on page 3 in Japanese Patent Laid-open No. 5-3793.

(vii) Hosts preferable for L-arginine production

Following bacterial strains are exemplified as the bacteria belonging to the genus Escherichia:

Escherichia coli AJ11593 (FERM P-5616), see upper-left column on page 468 in Japanese Patent Laid-open No. 57-5693; Escherichia coli AJ11594 (FERM P-5617), see upper-right column on page 468 in Japanese Patent Laid-open No. 57-5693.

Following bacterial strains are exemplified as the coryneform bacteria:

Brevibacterium flavum AJ12144 (FERM P-7642), see column 4 on page 174 in Japanese Patent Publication No. 5-27388: Corynebacterium glutamicum AJ12145 (FERM P-7643), see column 4 on page 174 in Japanese Patent Publication No. 5-27388; Brevibacterium flavum ATCC 21493, see Table 1 on page 3 in Japanese Patent Laid-open No. 5-3793; Corynebacterium glutamicum ATCC 21659, see Table 1 on page 3 in Japanese Patent Laid-open No. 5-3793.

(viii) Hosts preferable for L-proline production

Following bacterial strains are exemplified as the bacteria belonging to the genus Escherichia:

Escherichia coli AJ11543 (FERM P-5483), see lower-left column on page 435 in Japanese Patent Laid-open No. 56-144093; Escherichia coli AJ11544 (FERM P-5484), see lower-left column on page 435 in Japanese Patent Laid-open No. 56-144093.

Following bacterial strains are exemplified as the coryneform bacteria:

Brevibacterium lactofermentum AJ11225 (FERM P-4370), see upper-left column on page 473 in Japanese Patent Laid-open No. 60-87788; Brevibacterium flavum AJ11512 (FERM P-5332), see column 2 on page 185 in Japanese Patent Publication No. 62-36679; Brevibacterium flavum AJ11513 (FERM P-5333), see column 2 on page 185 in Japanese Patent Publication No. 62-36679; Brevibacterium flavum AJ11514 (FERM P-5334), see column 2 on page 185 in Japanese Patent Publication No. 62-36679; Corynebacterium glutamicum AJ11522 (FERM P-5342), see column 2 on page 185 in Japanese Patent Publication No. 62-36679; Corynebacterium glutamicum AJ11523 (FERM P-5343), see column 2 on page 185 in Japanese Patent Publication No. 62-36679. (2) Cultivation Method

The method for cultivating the aforementioned hosts is not especially different from a cultivation method for amino acid-producing microorganisms in the prior art. Namely, an ordinary medium is used containing a carbon source, a nitrogen source and inorganic ions, and optionally organic trace nutrients such as amino acids, vitamins and the like.

As the carbon source, glucose, sucrose, lactose and the like, as well as starch hydrolysate, whey, molasses and the like containing them may be used. As the nitrogen source, ammonia gas, aqueous ammonium, ammonium salt and the like can be used. Incidentally, when a nutrient requiring mutant strain for amino acids or the like is used as the host, it is necessary to suitably add the nutrient such as amino acid or the like required by the strain to the medium. An example of the medium for lysine production is shown in Table 1 below as a medium to be used for amino acid production. Incidentally, calcium carbonate is added to other components after being separately sterilized.

TABLE 1______________________________________Medium component Blending amount______________________________________glucose 5 g/dl(NH.sub.4).sub.2 SO.sub.4 2.5 g/dlKH.sub.2 PO.sub.4 0.2 g/dlMgSO.sub.4.7H.sub.2 O 0.1 g/dlyeast extract 0.05 g/dlthiamine hydrochloride 1 .mu.g/lbiotin 300 .mu.g/lFeSO.sub.4.7H.sub.2 O 1 mg/dlMnSO.sub.4.4H.sub.2 O 1 mg/dlcalcium carbonate 2.5 g/dl(pH 7.0)______________________________________

The cultivation is performed until generation and accumulation of amino acids substantially stop while suitably controlling pH and temperature of the medium under an aerobic condition. In order to collect amino acids thus accumulated in the cultivated medium, an ordinary method can be applied.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows growth inhibition by 3-bromopyruvate.

FIG. 2 shows growth inhibition by aspartate-.beta.-hydrazide.

FIG. 3 shows growth inhibition by DL-threo-.beta.-hydroxyaspartate.

FIG. 4 shows effects of inhibition recovering substances on 3-bromopyruvate.

FIG. 5 shows effects of inhibition recovering substances on aspartate-.beta.-hydrazide.

FIG. 6 shows effects of inhibition recovering substances on DL-threo-.beta.-hydroxyaspartate.

FIG. 7 shows influences exerted on growth by growth recovering factors.

FIG. 8 shows inhibition of phosphoenolpyruvate carboxylase by growth inhibitory substances.

FIG. 9 shows inhibition of phosphoenolpyruvate carboxylase of the present invention by aspartic acid.

FIG. 10 shows inhibition of phosphoenolpyruvate carboxylase of the present invention by aspartic acid.

FIG. 11 shows a method for introducing mutation into a phosphoenolpyruvate carboxylase gene.

FIG. 12 shows influences exerted by aspartic acid on activities of wild type and mutant phosphoenolpyruvate carboxylase in which 438th arginine was substituted with cysteine counted from the N-terminus.

FIG. 13 shows the influence exerted by (a) 1-10 mM aspartic acid and (b) 1-50 mM aspartic acid on the activities of the wild-type E. coli phosphoenopyruvate carboxylase (solid circles) and the mutants K491A (open squares), K605A (open circles), and K620S (open diamonds).

BEST MODE FOR CARRYING OUT THE INVENTION

The present invention will be explained more concretely below with reference to Examples.

EXAMPLE 1

Acquisition of Mutant Phosphoenolpyruvate Carboxylase Gene

A mutant gene was prepared by using a plasmid pS2 obtained by inserting a phosphoenolpyruvate carboxylase gene having been cloned and determined for its base sequence into a SalI site of a vector plasmid pBR322. pS2 has an ampicillin resistance gene as a drug resistance marker gene (Sabe, H. et al., Gene, 31, 279-283 (1984)). The nucleotide sequence of the phosphoenolpyruvate carboxylase gene contained in pS2 is the same as that contained in the aforementioned plasmid pT2.

pS2 DNA was treated at 75.degree. C. for 2 hours with a hydroxylamine treating solution (20 .mu.g/ml pS2 DNA, 0.05M sodium phosphate (pH 6.0), 1 mM EDTA, 0.4M hydroxylamine). Because of influence by pH on the hydroxylamine treatment, 80 .mu.l of 1M hxydroxylamine.HCl and 1 mM EDTA solution having a pH adjusted to 6.0 with sodium hydroxide, 100 .mu.l of 0.1M sodium phosphate (pH 6.0) and 1 mM EDTA solution, and TE (10 mM Tris-HCl, 1 mM EDTA) buffer containing 2 .mu.g of pS2 DNA were mixed, to finally provide 200 .mu.l with water.

The aforementioned condition is a condition in which transformants has a survival ratio of 0.2% based on a state before the treatment in an ampicillin-containing medium when Escherichia coli HB101 is transformed with pS2 after the treatment.

Escherichia coli HB101 was transformed with pS2 treated with hydroxylamine, which was spread on a solid plate medium containing ampicillin to obtain about 10000 colonies of transformants. They were suspended in a liquid medium, and spread on a solid plate medium containing any one of 3-bromopyruvate (3BP), aspartate-.beta.-hydroxamate (AHX), aspartate-.beta.-hydrazide (AHY) and DL-threo-.beta.-hydroxyaspartate (.beta. HA) as the analog compounds of aspartic acid at a concentration near a minimal inhibitory concentration to give 10.sup.3 to 10.sup.5 cells per one medium plate, and growing colonies were selected.

From 100 strains of analog compound resistant strains thus obtained, phosphoenolpyruvate carboxylase produced by each of them was partially purified in accordance with a method described in The Journal of Biochemistry, Vol. 67, No. 4 (1970), and inhibition of enzyme activity by the analog compounds was investigated. Measurement of the enzyme activity was performed in the same manner as described above.

Further, plasmids were isolated from bacterial strains producing mutant enzymes with activities not inhibited by the analog compounds, and were introduced into Escherichia coli PCR1 as a phosphoenolpyruvate carboxylase deficient strain (Sabe, H. et al., Gene, 31, 279-283 (1984)), to confirm production of the mutant enzymes.

Five transformants harboring mutant enzyme genes were thus obtained. As a result of determination of base sequences of these genes, 2 strains had the same mutation, and 4 kinds of mutant genes were obtained. The transformants harboring them were designated as AJ12907, AJ12908, AJ12909 and AJ12910, and were deposited in National Institute of Bioscience and Human Technology of Agency of Industrial Science and Technology1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan; zip code 305) on Aug. 3, 1993 under the deposition numbers of FERM P-13774, FERM P-13775, FERM P-13776 and FERM P-13777, transferred from the original deposition to international deposition based on Budapest Treaty on Jul. 11, 1994 and has been deposited as deposition numbers of FERM BP-4734, FERM BP-4735, FERM BP-4736, FERM BP-4737, respectively in this order. Further, the plasmids possessed by them were designated as pBP5, pHA19, pBP122 and pR6 respectively in this order. Mutations possessed by the phosphoenolpyruvate carboxylase genes contained in each of the plasmids are shown in Table 2. Numerical values in the table indicate nucleotide numbers or amino acid numbers in SEQ ID NO:1.

TABLE 2______________________________________ Amino acid replacementTransformant Plasmid Mutation associated with mutation______________________________________AJ12907 pBP5 .sup.2109 G.fwdarw.A .sup.625 Glu.fwdarw.LysAJ12908 pHA19 .sup. 901 G.fwdarw.A .sup.222 Arg.fwdarw.His .sup. 903 G.fwdarw.A .sup.223 Glu.fwdarw.LysAJ12909 pBP122 .sup.1099 C.fwdarw.T .sup.288 Ser.fwdarw.Phe .sup.1101 G.fwdarw.A .sup.289 Glu.fwdarw.Lys .sup.1889 G.fwdarw.A .sup.551 Met.fwdarw.Ile .sup.2646 G.fwdarw.A .sup.804 Glu.fwdarw.LysAJ12910 pR6 .sup.2835 G.fwdarw.A .sup.867 Ala.fwdarw.Thr______________________________________

Incidentally, selection was performed for AJ12907 and AJ12909 in a medium containing 500 .mu.g/ml of 3BP, for AJ12908 in a medium containing 1000 .mu.g/ml of .beta.HA, and for AJ12910 in a medium containing 500 .mu.g/ml of AHY.

EXAMPLE 2

Mutant Phosphoenolpyruvate Carboxylase

Sensitivity to aspartic acid was investigated for phosphoenolpyruvate carboxylases produced by the aforementioned 4 transformants. These bacterial strains are deficient in the phosphoenolpyruvate carboxylase gene originating from the host, so that produced phosphoenolpyruvate carboxylase originates from the plasmid.

Sensitivity to aspartic acid was investigated in accordance with a known method (Yoshinaga, T., Izui, K. and Katsuki, H., J. Biochem., 68, 747-750 (1970)). Namely, as a result of measurement of the enzyme activity produced by each of the transformants or Escherichia coli harboring pS2 in the presence of acetyl-coenzyme A known to affect the activity in an activity measurement system at a concentration of 0.1 mM or 1 mM, sensitivity to aspartic acid was measured as shown in FIGS. 9 and 10.

According to the result, it is apparent that the wild type enzyme loses its activity when aspartic acid is at a high concentration, while the mutant phosphoenolpyruvate carboxylase of the present invention substantially continues to maintain its activity.

EXAMPLE 3

Fermentative Production of L-threonine by Escherichia Coli with Introduced Mutant Phosphoenolpyruvate Carboxylase

As threonine-producing bacteria of Escherichia coli, B-3996 strain (Japanese Patent Laid-open No. 3-501682 (PCT)) has the highest production ability among those known at present. Thus upon evaluation of the mutant phosphoenolpyruvate carboxylase, B-3996 was used as the host. This B-3996 strain has been deposited in Research Institute for Genetics and Industrial Microorganism Breeding under a registration number of RIA 1867. Further, pBP5 was selected as the mutant phosphoenolpyruvate carboxylase to be evaluated, which was subjected to an experiment.

The plasmid pBP5 having the mutant phosphoenolpyruvate carboxylase was introduced into Escherichia coli B-3996 in accordance with a method of Hanahan (J. Mol. Biol., Vol. 106, p577 (1983)), and a transformant was isolated. As a control, Escherichia coli B-3996 was transformed in the same manner with pS2 as the plasmid to express the wild type phosphoenolpyruvate carboxylase gene.

When Escherichia coli B-3996 and the transformants therefrom were respectively inoculated in a 500 ml of Sakaguchi flask poured with 20 ml of a medium having a composition in Table 3, and cultivated at 37.degree. C. for 40 hours to investigate a production amount of L-threonine, then results shown in Table 4 were obtained. Incidentally, the aforementioned medium was separated into two: glucose and MgSO.sub.4.7H.sub.2 O, and the other components, and adjusted to have a pH of 7.0 with KOH followed by autoclaving at 115.degree. C. for 10 minutes, and then, after mixing them, separately sterilized CaCO.sub.3 was added by 30 g/l.

TABLE 3______________________________________Component Blending amount (g/l)______________________________________glucose 40(NH.sub.4).sub.2 SO.sub.4 16KH.sub.2 PO.sub.4 1MgSO.sub.4.7H.sub.2 O 1FeSO.sub.4.7H.sub.2 O 0.01MnSO.sub.4.5H.sub.2 O 0.01yeast extract (Difco) 2L-Met 0.5CaCO.sub.3 30______________________________________ TABLE 4______________________________________ Threonine production amountBacterial strain (g/l)______________________________________Escherichia coli B-3996 15.7Escherichia coli B-3996/pS2 15.8Escherichia coli B-3996/pBP5 16.8______________________________________

As clarified from the result, Escherichia coli B-3996/pBP5 harboring the mutant enzyme expression plasmid having the DNA sequence of the present invention had an improved threonine-producing ability as compared with Escherichia coli B-3996/pS2 harboring the plasmid to express the wild type enzyme.

EXAMPLE 4

Fermentative Production of L-glutamic Acid by Escherichia Coli with Introduced Mutant Phosphoenolpyruvate Carboxylase

As glutamic acid-producing bacteria of Escherichia coli, Escherichia coli AJ-12628 described in Japanese Patent Laid-open No. 4-11461 has the highest production ability among those known at present. Thus upon evaluation of the mutant phosphoenolpyruvate carboxylase, AJ-12628 was used as the host.

The AJ-12628 strain has been deposited in National Institute of Bioscience and Human Technology of Agency of Industrial Science and Technology under a registration number of FERM BP-385 Further, pBP5 was selected as the mutant phosphoenolpyruvate carboxylase to be evaluated, which was subjected to an experiment.

The plasmid pBP5 having the mutant phosphoenolpyruvate carboxylase was introduced into Escherichia coli AJ-12628 in accordance with a method of Hanahan (J. Mol. Biol., Vol. 106, p577 (1983)), and a transformant was isolated. In the same manner, a transformant of Escherichia coli AJ-12628 with pS2 was isolated.

When Escherichia coli AJ-12628 and the transformants therefrom were respectively inoculated in a 500 ml of Sakaguchi flask poured with 20 ml of a medium having a composition in Table 5, and cultivated at 37.degree. C. for 36 hours to investigate a production amount of L-glutamic acid, then results shown in Table 6 were obtained. Incidentally, the aforementioned medium was separated into two: glucose and MgSO.sub.4.7H.sub.2 O, and the other components, and adjusted to have a pH of 7.0 with KOH followed by autoclaving at 115.degree. C. for 10 minutes, and then, after mixing them, separately sterilized CaCO.sub.3 was added by 30 g/l.

TABLE 5______________________________________Component Blending amount (g/l)______________________________________glucose 40(NH.sub.4).sub.2 SO.sub.4 16KH.sub.2 PO.sub.4 1MgSO.sub.4.7H.sub.2 O 1FeSO.sub.4.7H.sub.2 O 0.01MnSO.sub.4.5H.sub.2 O 0.01yeast extract (Difco) 2CaCO.sub.3 30______________________________________ TABLE 6______________________________________ Glutamic acid productionBacterial strain amount (g/l)______________________________________Escherichia coli AJ-12628 18.0Escherichia coli AJ-12628/pS2 18.3Escherichia coli AJ-12628/pBP5 19.6______________________________________

As clarified from the result, Escherichia coli AJ-12628/pBP5 harboring the mutant enzyme expression plasmid having the DNA sequence of the present invention had an improved glutamate-producing ability as compared with Escherichia coli AJ-12628/pS2 harboring the plasmid to express the wild type enzyme.

EXAMPLE 5

Production of L-lysine by Coryneform Bacterium with Introduced Mutant Phosphoenolpyruvate Carboxylase

In order to introduce and express the mutant gene in a coryneform bacterium, a promoter originating from a bacterium belonging to the genus Brevibacterium was obtained, and was ligated with the mutant gene to prepare an expression type plasmid. Further, it was introduced into a bacterium belonging to the genus Brevibacterium to perform production of L-lysine.

<1> Acquisition of Aspartokinase (AK) Gene Originating from Bacterium Belonging to the Genus Brevibacterium

Chromosomal DNA was prepared according to an ordinary method from a Brevibacterium lactofermentum (Corynebacterium glutamicum) wild strain (ATCC 13869). An AK gene was amplified from the chromosomal DNA by PCR (polymerase chain reaction; see White, T. J. et al., Trends Genet., 5, 185 (1989)). For DNA primers used in the amplification, an oligonucleotide of 23 mer (SEQ ID NO:3) and an oligonucleotide of 21 mer (SEQ ID NO:4) were synthesized to amplify a region of about 1643 bp coding for the AK gene based on a sequence known in Corynebacterium glutamicum (see Molecular Microbiology (1991) 5 (5), 1197-1204, Mol. Gen. Genet. (1990) 224, 317-324).

The synthesis of DNA was performed in accordance with an ordinary phosphoamidite method (see Tetrahedron Letters (1981), 22, 1859) using a DNA synthesizer model 380B produced by Applied Biosystems Co. In the PCR reaction, DNA Thermal Cycler PJ2000 type produced by Takara Shuzo Co., Ltd. was used, and gene amplification was performed by using Taq DNA polymerase in accordance with a method designated by the manufacturer.

An amplified gene fragment of 1643 kb was confirmed by agarose gel electrophoresis, and then the fragment cut out from the gel was purified by an ordinary method, and was cleaved with restriction enzymes NruI (produced by Takara Shuzo Co., Ltd.) and EcoRI (produced by Takara Shuzo Co., Ltd.). pHSG399 (see Takeshita, S. et al.; Gene (1987), 61, 63-74) was used for a cloning vector for the gene fragment. pHSG399 was cleaved with a restriction enzyme SmaI (produced by Takara Shuzo Co., Ltd.) and a restriction enzyme EcoRI, and ligated with the amplified AK gene fragment.

Ligation of DNA was performed by a designated method by using a DNA ligation kit (produced by Takara Shuzo Co., Ltd.). In such a manner, a plasmid was manufactured in which pHSG399 was ligated with the AK gene fragment amplified from Brevibacterium chromosome. The plasmid having the AK gene originating from ATCC 13869 as the wild strain was designated as p399AKY.

<2> Determination of Base Sequence of AK Gene of Brevibacterium lactofermentum

The AK plasmid, p399AKY was prepared, and the base sequence of the AK gene was determined. Determination of the base sequence was performed in accordance with the method of Sanger et al. (F. Sanger et al.: Proc. Natl. Acad. Sci. USA, 74, 5463 (1977) and so forth). Results are shown in SEQ ID NO:5 and SEQ ID NO:7. The DNA fragments have two open reading frames which correspond to .alpha.-subunit and .beta.-subunit of AK, respectively. In SEQ ID NO:5 and SEQ ID NO:7, amino acid sequences corresponding to each of the open reading frames are shown together with nucleotide sequences. Further, only the amino acid sequences corresponding to each of the open reading frames are shown in SEQ ID NO:6 and SEQ ID NO:8.

<3> Preparation of Phosphoenolpyruvate Carboxylase Expression Plasmid

SalI fragments of about 4.4 kb containing phosphoenolpyruvate carboxylase genes were extracted from pS2 as the plasmid having the wild type phosphoenolpyruvate carboxylase gene and pBP5 as the plasmid having the obtained mutant phosphoenolpyruvate carboxylase gene, and inserted into a SalI site of a plasmid vector pHSG399 universally used for Escherichia coli. Manufactured plasmids were designated as pHS2 for the wild type and as pHBP5 for the mutant.

In order to convert pHS2 and pHPB5 into plasmids to express in Brevibacterium, a promoter and a replication origin of a plasmid for functioning in Brevibacterium were introduced. As the promoter, a gene fragment containing one from 1st NruI site to 207th ApaLI site of the base sequence, which was postulated to be a promoter region of the cloned AK gene, was extracted from p399AXY, and inserted into an AvaI site located about 60 bp before the structural genes of pHS2 and pHBP5 to allow the transcription direction to be in a regular direction.

Further, a gene fragment to enable autonomously replication of the plasmid in Brevibacterium, namely the replication origin of the plasmid was introduced into a site located on the vector. A gene fragment containing the replication origin of the plasmid was extracted from a vector pHC4 for Brevibacterium (see paragraph No. 10 in Japanese Patent Laid-open No. 5-7491; Escherichia coli AJ12039 harboring the same plasmid is deposited in National Institute of Bioscience and Human Technology of Agency of Industrial Science and Technology, to which a deposition number of FERM P12215 is given), and restriction enzyme sites at both termini were modified into PstI sites by introduction of linkers.

This fragment was introduced into a PstI site in a vector portion of the plasmid added with the promoter derived from Brevibacterium. Constructed phosphoenolpyruvate carboxylase-expressing plasmids were designated as pHS2B for a wild type phosphoenolpyruvate carboxylase plasmid originating from pS2 and as pHBP5B for a mutant phosphoenolpyruvate carboxylase plasmid originating from pBP5, respectively.

<4> Production of L-lysine by Using Phosphoenolpyruvate Carboxylase Expression Type Plasmid

Prepared pHS2B and pHBP5B were respectively introduced into AJ3463 as an L-lysine-producing bacterium of Brevibacterium lactofermentum (see Japanese Patent Publication No. 51-34477). For introduction of the gene, a transformation method employing electric pulse was used (see Japanese Patent Laid-open No. 2-207791). The host strain and transformants were cultivated with shaking for 72 hours at 31.5.degree. C. in a lysine production medium having a composition in Table 7. The aforementioned medium was prepared such that those except for CaCO.sub.3 among the components listed in the table were added to 1 l of water, and adjusted to have a pH of 8.0 with KOH followed by autoclaving at 115.degree. C. for 15 minutes, and then CaCO.sub.3 having been subjected to heat sterilization was further added. Accumulated amounts of L-lysine in the medium after cultivation are shown in Table 8.

TABLE 7______________________________________Component Blending amount in 1 L______________________________________glucose 100 g(NH.sub.4).sub.2 SO.sub.4 55 gsoybean concentrate* 35 mlKH.sub.2 PO.sub.4 1 gMgSO.sub.4.7H.sub.2 O 1 gvitamin B1 20 gbiotin 5 gnicotinic acid amide 5 mgFeSO.sub.4.7H.sub.2 O 0.01 gMnSO.sub.4.5H.sub.2 O 0.01 gCaCO.sub.3 50 g______________________________________ *product of Ajinomoto Co., Ltd. (trade name: Mamenou) TABLE 8______________________________________ Lysine productionBacterial strain amount (g/l)______________________________________Brevibacterium lactofermentum AJ3463 20.0Brevibacterium lactofermentum AJ3463/pHS2B 22.0Brevibacterium lactofermentum AJ3463/pHBP5B 25.0______________________________________

As shown in the result, Brevibacterium lactofermentum AJ3463/pHBP5B harboring the mutant enzyme expression plasmid having the DNA sequence of the present invention had an improved lysine-producing ability as compared with Brevibacterium lactofermentum AJ3463/pHS2B harboring the plasmid to express the wild type enzyme.

EXAMPLE 6

Another Example of Mutant Phosphoenolpyruvate Carboxylase of the Present Invention and its Gene

<1> Preparation of Mutant Phosphoenolpyruvate Carboxylase Gene

Upon preparation of DNA coding for a mutant phosphoenolpyruvate carboxylase, a phosphoenolpyruvate carboxylase gene cloned in a plasmid pT2 was used as a material.

A host, which is allowed to harbor the plasmid pT2, is preferably deficient in phosphoenolpyruvate carboxylase gene in order to detect only the activity of phosphoenolpyruvate carboxylase originating from the plasmid. Escherichia coli F15 (Hfr, recA1, met, .DELTA.(ppc-argECBH), Tn10) was used as such a deficient strain. Escherichia coli AJ-12873, which is allowed to harbor pT2 in F15 strain, is deposited as FERM P-13752 in National Institute of Bioscience and Human Technology of Agency of Industrial Science and Technology (1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan; zip code 305) on Jul. 15, 1993, transferred from the original deposition to international deposition based on Budapest Treaty on Jul. 11, 1994 and has been deposited as deposition number of FERM BP-4732. In addition, an entire base sequence of pT2 is shown in SEQUENCE ID NO:1.

In order to replace a codon of 438th arginine of the phosphoenolpyruvate carboxylase into a codon of cysteine by using pT2, the Overlapping Extension method (Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. K. and Pease, L. R., Gene, 77, 51-59 (1989)) utilizing the PCR (Polymerase Chain Reaction) method was used.

Incidentally, the PCR method is a method in which an amplification cycle comprising thermal denaturation of double strand DNA into single strand DNA, annealing of oligonucleotide primers corresponding to sequences at both ends of a site aimed to be amplified and the aforementioned thermally denatured DNA, and polymerase reaction using the aforementioned oligonucleotides as primers is repeated, thereby the aforementioned DNA sequence is amplified in a manner of an exponential function.

A region subjected to site specific mutation by the PCR method is shown in FIG. 11. The primers used in the present invention were 4 species of a primer c (SEQUENCE ID NO:11, corresponding to base Nos. 1535-1554 in SEQUENCE ID NO:1) having a sequence in the vicinity of the codon of 438th arginine, a primer b (SEQUENCE ID NO:10) having a sequence complement to the primer c, a primer a (SEQUENCE ID NO:9, corresponding to base Nos. 1185-1200 in SEQUENCE ID NO:1) having a sequence upstream therefrom, and a primer d (SEQUENCE ID NO:12, corresponding to base Nos. 2327-2342 in SEQUENCE ID NO:1) having a sequence complement to a downstream sequence.

In the primer b and the primer c, the codon (CGT) of 438th arginine was replaced with a codon (TGT) of cysteine. This replacement may use TGC which is another codon of cysteine. Further, C of the third letter of a codon (AAC) of 435th asparagine was replaced with T, and hence an EcoRI site was internally introduced with no replacement of amino acid, so that a mutant plasmid could be selected by using it as an index. However, this mutation is not essential to the present invention.

When the PCR reaction was performed by using pT2 DNA as a template and the primer a and the primer b as the primers, a fragment from the upstream of the mutation site to the mutation site (AB fragment in FIG. 11) was amplified. Further, when the PCR reaction was performed by using the primer c and the primer d, a fragment downstream from the mutation site (CD fragment in FIG. 11) was amplified. When each of the amplified products (AB, CD) was annealed again after thermal denaturation to perform a polymerase reaction, they were ligated to obtain a fragment (AD fragment in FIG. 11). Incidentally, the PCR reaction was performed by repeating 30 cycles of each comprising heating at 94.degree. C. for 1 minute followed by denaturation (94.degree. C., 1.5 minutes), annealing (50.degree. C., 2 minutes), and elongation reaction by polymerase (72.degree. C., 3.5 minutes). In addition, reaction compositions are shown in Table 9.

TABLE 9______________________________________Composition PCR fragment(( ): final conc.) AB CD AD______________________________________H.sub.2 O 53.5 53.5 53.510-fold reaction buffer 10 10 10mixture of 1.25 mM dNTP 16 16 1620 .mu.M primer a (1 .mu.M) 5 -- 520 .mu.M primer b (1 .mu.M) 5 -- --20 .mu.M primer c (1 .mu.M) -- 5 --20 .mu.M primer d (1 .mu.M) -- 5 510 .mu.g/.mu.l pT2 (0.1 .mu.g) 10 10 --PCR fragment AB* -- -- 5PCR fragment CD* -- -- 52.5 U/.mu.l Tag polymerase 0.5 0.5 0.5total amount 100 .mu.l 100 .mu.l 100 .mu.l______________________________________ *PCR fragments AB and CD were prepared, after the PCR reaction, by recovering 10 .mu.l thereof from polyacrylamide gel, and dissolving it in 5 .mu.l of TE (10 mM TrisHCl (pH 8.0), 1 mM EDTA (pH 8.0)).

In the AD fragment obtained as described above, a BssHII site (1231-1236 in SEQ ID NO:1) at the upstream side and a SplI site (2249-2254 in SEQ ID NO:1) at the downstream side were present, so that complete digestion was performed with these enzymes to make replacement for a corresponding region of the plasmid pT2 (FIG. 11).

<2> Selection of Inhibition-desensitized Phosphoenolpyruvate Carboxylase

Escherichia coli was transformed with a plasmid obtained as described above, and a transformed strain was cultivated to recover the plasmid to select one cleaved by EcoRI. With respect to selected DNA, a base sequence of the region amplified by the aforementioned PCR method was determined by the dideoxy method to confirm that base replacement as exactly aimed was introduced. This plasmid was designated as pT2R438C. A strain (AJ12874) obtained by introducing this plasmid into the aforementioned Escherichia coli F15 has been deposited as FERM P-13753 in National Institute of Bioscience and Human Technology of Agency of Industrial Science and Technology (1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan; zip code 305) on Jul. 15, 1993, transferred from the original deposition to international deposition based on Budapest Treaty on Jul. 11, 1994 and has been deposited as deposition number of FERM BP-4733.

The base sequence of pT2R438C is a sequence in which 1541th and 1550th nucleotides are replaced from C to T respectively in SEQ ID NO:1.

<3> Confirmation of Desensitization of Inhibition of Mutant Phosphoenolpyruvate Carboxylase by Aspartic Acid

Sensitivity to aspartic acid was investigated for phosphoenolpyruvate carboxylase produced by the aforementioned Escherichia coli AJ12874 harboring pT2R438C. Incidentally, as described above, because the Escherichia coli F15 is deficient in phosphoenolpyruvate carboxylase, phosphoenolpyruvate carboxylase produced by AJ12874 originates from the plasmid.

Sensitivity to aspartic acid was investigated in accordance with a known method (Yoshinaga, T., Izui, K. and Katsuki, H., J. Biochem., 68, 747-750 (1970)). Namely, as a result of measurement of the enzyme activity in the presence of acetyl-coenzyme A known to affect the activity in an activity measurement system at a concentration of 1 mM or 2 mM, sensitivity to aspartic acid was measured as shown in FIG. 12.

It is apparent that the wild type enzyme substantially loses its activity when aspartic acid is at a high concentration, while the mutant phosphoenolpyruvate carboxylase of the present invention continues to maintain its activity.

<4> Preparation of Mutant Phosphoenolpyruvate Carboxylase Gene (II)

In order to replace a codon of 620th lysine with a codon of serine in the phosphoenolpyruvate carboxylase gene carried on the plasmid pT2, the Overlapping Extension method (Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. K. and Pease, L. R., Gene, 77, 51-59 (1989)) utilizing the PCR (Polymerase Chain Reaction) method was used. Concrete procedures were in accordance with the method described in <1>. A plasmid carrying a mutant gene constructed with aimed replacement was designated as pT2K620S. Further, an obtained mutant enzyme was designated as K620S mutant enzyme.

<5> Confirmation of Desensitization of Inhibition by Aspartic Acid Concerning Mutant Phosphoenolpyruvate Carboxylase.

With respect to the phosphoenolpyruvic carboxylase produced by a transformant obtained by introducing the plasmid pT2K620S into the aforementioned Escherichia coli F15, sensitivity to aspartic acid was investigated. Incidentally, as described above, since the Escherichia coli F15 lacks phosphoenolpyruvate carboxylase, any phosphoenolpyruvate carboxylase produced by the transformant originates from the plasmid.

Sensitivity to aspartic acid was investigated in accordance with a known method (Yoshinaga, T., Izui, K. and Katsuki, H., J. Biochem., 68, 747-750 (1970)). Namely, as a result of measurement of the enzyme activity in the presence of acetyl-coenzyme A known to affect the activity in an activity measurement system at a concentration of 1 mM or 2 mM, sensitivity to aspartic acid was measured as shown in FIG. 13.

It is apparent that the wild enzyme substantially loses its activity when aspartic acid is at a high concentration, while the type phosphoenolpyruvate carboxylase of the present invention continues to maintain its activity.

In FIG. 13, sensitivity to aspartic acid is also depicted for a mutant phosphoenolpyruvate carboxylase in which 650th lysine is replaced with serine (K650A mutant enzyme), and for a mutant phosphoenolpyruvate carboxylase in which 491th lysine is replaced with serine (K491A mutant enzyme). In the case of these mutant enzymes, inhibition by aspartic acid was not desensitized.

INDUSTRIAL APPLICABILITY

The DNA sequence of the present invention codes for the mutant phosphoenolpyruvate carboxylase, and the microorganism harboring this DNA sequence produces the aforementioned enzyme.

The mutant phosphoenolpyruvate carboxylase of the present invention does not substantially undergo activity inhibition by aspartic acid, so that it can be utilized for fermentative production of amino acids subjected to regulation of biosynthesis by aspartic acid and the like.

__________________________________________________________________________# SEQUENCE LISTING- (1) GENERAL INFORMATION:- (iii) NUMBER OF SEQUENCES: 12- (2) INFORMATION FOR SEQ ID NO:1:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 5186 base (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: circular- (ii) MOLECULE TYPE: DNA (genomic)- (iv) ANTI-SENSE: NO- (vi) ORIGINAL SOURCE:#coli (A) ORGANISM: Escherichia- (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 237..2888- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:- TCGACCGGCG ATTTTTTAAC ATTTCCATAA GTTACGCTTA TTTAAAGCGT CG - #TGAATTTA 60- ATGACGTAAA TTCCTGCTAT TTATTCGTTT GCTGAAGCGA TTTCGCAGCA TT - #TGACGTCA 120- CCGCTTTTAC GTGGCTTTAT AAAAGACGAC GAAAAGCAAA GCCCGAGCAT AT - #TCGCGCCA 180- ATGCGACGTG AAGGATACAG GGCTATCAAA CGATAAGATG GGGTGTCTGG GG - #TAAT 236- ATG AAC GAA CAA TAT TCC GCA TTG CGT AGT AA - #T GTC AGT ATG CTC GGC 284Met Asn Glu Gln Tyr Ser Ala Leu Arg Ser As - #n Val Ser Met Leu Gly# 15- AAA GTG CTG GGA GAA ACC ATC AAG GAT GCG TT - #G GGA GAA CAC ATT CTT 332Lys Val Leu Gly Glu Thr Ile Lys Asp Ala Le - #u Gly Glu His Ile Leu# 30- GAA CGC GTA GAA ACT ATC CGT AAG TTG TCG AA - #A TCT TCA CGC GCT GGC 380Glu Arg Val Glu Thr Ile Arg Lys Leu Ser Ly - #s Ser Ser Arg Ala Gly# 45- AAT GAT GCT AAC CGC CAG GAG TTG CTC ACC AC - #C TTA CAA AAT TTG TCG 428Asn Asp Ala Asn Arg Gln Glu Leu Leu Thr Th - #r Leu Gln Asn Leu Ser# 60- AAC GAC GAG CTG CTG CCC GTT GCG CGT GCG TT - #T AGT CAG TTC CTG AAC 476Asn Asp Glu Leu Leu Pro Val Ala Arg Ala Ph - #e Ser Gln Phe Leu Asn# 80- CTG GCC AAC ACC GCC GAG CAA TAC CAC AGC AT - #T TCG CCG AAA GGC GAA 524Leu Ala Asn Thr Ala Glu Gln Tyr His Ser Il - #e Ser Pro Lys Gly Glu# 95- GCT GCC AGC AAC CCG GAA GTG ATC GCC CGC AC - #C CTG CGT AAA CTG AAA 572Ala Ala Ser Asn Pro Glu Val Ile Ala Arg Th - #r Leu Arg Lys Leu Lys# 110- AAC CAG CCG GAA CTG AGC GAA GAC ACC ATC AA - #A AAA GCA GTG GAA TCG 620Asn Gln Pro Glu Leu Ser Glu Asp Thr Ile Ly - #s Lys Ala Val Glu Ser# 125- CTG TCG CTG GAA CTG GTC CTC ACG GCT CAC CC - #A ACC GAA ATT ACC CGT 668Leu Ser Leu Glu Leu Val Leu Thr Ala His Pr - #o Thr Glu Ile Thr Arg# 140- CGT ACA CTG ATC CAC AAA ATG GTG GAA GTG AA - #C GCC TGT TTA AAA CAG 716Arg Thr Leu Ile His Lys Met Val Glu Val As - #n Ala Cys Leu Lys Gln145 1 - #50 1 - #55 1 -#60- CTC GAT AAC AAA GAT ATC GCT GAC TAC GAA CA - #C AAC CAG CTG ATG CGT 764Leu Asp Asn Lys Asp Ile Ala Asp Tyr Glu Hi - #s Asn Gln Leu Met Arg# 175- CGC CTG CGC CAG TTG ATC GCC CAG TCA TGG CA - #T ACC GAT GAA ATC CGT 812Arg Leu Arg Gln Leu Ile Ala Gln Ser Trp Hi - #s Thr Asp Glu Ile Arg# 190- AAG CTG CGT CCA AGC CCG GTA GAT GAA GCC AA - #A TGG GGC TTT GCC GTA 860Lys Leu Arg Pro Ser Pro Val Asp Glu Ala Ly - #s Trp Gly Phe Ala Val# 205- GTG GAA AAC AGC CTG TGG CAA GGC GTA CCA AA - #T TAC CTG CGC GAA CTG 908Val Glu Asn Ser Leu Trp Gln Gly Val Pro As - #n Tyr Leu Arg Glu Leu# 220- AAC GAA CAA CTG GAA GAG AAC CTC GGC TAC AA - #A CTG CCC GTC GAA TTT 956Asn Glu Gln Leu Glu Glu Asn Leu Gly Tyr Ly - #s Leu Pro Val Glu Phe225 2 - #30 2 - #35 2 -#40- GTT CCG GTC CGT TTT ACT TCG TGG ATG GGC GG - #C GAC CGC GAC GGC AAC1004Val Pro Val Arg Phe Thr Ser Trp Met Gly Gl - #y Asp Arg Asp Gly Asn# 255- CCG AAC GTC ACT GCC GAT ATC ACC CGC CAC GT - #C CTG CTA CTC AGC CGC1052Pro Asn Val Thr Ala Asp Ile Thr Arg His Va - #l Leu Leu Leu Ser Arg# 270- TGG AAA GCC ACC GAT TTG TTC CTG AAA GAT AT - #T CAG GTG CTG GTT TCT1100Trp Lys Ala Thr Asp Leu Phe Leu Lys Asp Il - #e Gln Val Leu Val Ser# 285- GAA CTG TCG ATG GTT GAA GCG ACC CCT GAA CT - #G CTG GCG CTG GTT GGC1148Glu Leu Ser Met Val Glu Ala Thr Pro Glu Le - #u Leu Ala Leu Val Gly# 300- GAA GAA GGT GCC GCA GAA CCG TAT CGC TAT CT - #G ATG AAA AAC CTG CGT1196Glu Glu Gly Ala Ala Glu Pro Tyr Arg Tyr Le - #u Met Lys Asn Leu Arg305 3 - #10 3 - #15 3 -#20- TCT CGC CTG ATG GCG ACA CAG GCA TGG CTG GA - #A GCG CGC CTG AAA GGC1244Ser Arg Leu Met Ala Thr Gln Ala Trp Leu Gl - #u Ala Arg Leu Lys Gly# 335- GAA GAA CTG CCA AAA CCA GAA GGC CTG CTG AC - #A CAA AAC GAA GAA CTG1292Glu Glu Leu Pro Lys Pro Glu Gly Leu Leu Th - #r Gln Asn Glu Glu Leu# 350- TGG GAA CCG CTC TAC GCT TGC TAC CAG TCA CT - #T CAG GCG TGT GGC ATG1340Trp Glu Pro Leu Tyr Ala Cys Tyr Gln Ser Le - #u Gln Ala Cys Gly Met# 365- GGT ATT ATC GCC AAC GGC GAT CTG CTC GAC AC - #C CTG CGC CGC GTG AAA1388Gly Ile Ile Ala Asn Gly Asp Leu Leu Asp Th - #r Leu Arg Arg Val Lys# 380- TGT TTC GGC GTA CCG CTG GTC CGT ATT GAT AT - #C CGT CAG GAG AGC ACG1436Cys Phe Gly Val Pro Leu Val Arg Ile Asp Il - #e Arg Gln Glu Ser Thr385 3 - #90 3 - #95 4 -#00- CGT CAT ACC GAA GCG CTG GGC GAG CTG ACC CG - #C TAC CTC GGT ATC GGC1484Arg His Thr Glu Ala Leu Gly Glu Leu Thr Ar - #g Tyr Leu Gly Ile Gly# 415- GAC TAC GAA AGC TGG TCA GAG GCC GAC AAA CA - #G GCG TTC CTG ATC CGC1532Asp Tyr Glu Ser Trp Ser Glu Ala Asp Lys Gl - #n Ala Phe Leu Ile Arg# 430- GAA CTG AAC TCC AAA CGT CCG CTT CTG CCG CG - #C AAC TGG CAA CCA AGC1580Glu Leu Asn Ser Lys Arg Pro Leu Leu Pro Ar - #g Asn Trp Gln Pro Ser# 445- GCC GAA ACG CGC GAA GTG CTC GAT ACC TGC CA - #G GTG ATT GCC GAA GCA1628Ala Glu Thr Arg Glu Val Leu Asp Thr Cys Gl - #n Val Ile Ala Glu Ala# 460- CCG CAA GGC TCC ATT GCC GCC TAC GTG ATC TC - #G ATG GCG AAA ACG CCG1676Pro Gln Gly Ser Ile Ala Ala Tyr Val Ile Se - #r Met Ala Lys Thr Pro465 4 - #70 4 - #75 4 -#80- TCC GAC GTA CTG GCT GTC CAC CTG CTG CTG AA - #A GAA GCG GGT ATC GGG1724Ser Asp Val Leu Ala Val His Leu Leu Leu Ly - #s Glu Ala Gly Ile Gly# 495- TTT GCG ATG CCG GTT GCT CCG CTG TTT GAA AC - #C CTC GAT GAT CTG AAC1772Phe Ala Met Pro Val Ala Pro Leu Phe Glu Th - #r Leu Asp Asp Leu Asn# 510- AAC GCC AAC GAT GTC ATG ACC CAG CTG CTC AA - #T ATT GAC TGG TAT CGT1820Asn Ala Asn Asp Val Met Thr Gln Leu Leu As - #n Ile Asp Trp Tyr Arg# 525- GGC CTG ATT CAG GGC AAA CAG ATG GTG ATG AT - #T GGC TAT TCC GAC TCA1868Gly Leu Ile Gln Gly Lys Gln Met Val Met Il - #e Gly Tyr Ser Asp Ser# 540- GCA AAA GAT GCG GGA GTG ATG GCA GCT TCC TG - #G GCG CAA TAT CAG GCA1916Ala Lys Asp Ala Gly Val Met Ala Ala Ser Tr - #p Ala Gln Tyr Gln Ala545 5 - #50 5 - #55 5 -#60- CAG GAT GCA TTA ATC AAA ACC TGC GAA AAA GC - #G GGT ATT GAG CTG ACG1964Gln Asp Ala Leu Ile Lys Thr Cys Glu Lys Al - #a Gly Ile Glu Leu Thr# 575- TTG TTC CAC GGT CGC GGC GGT TCC ATT GGT CG - #C GGC GGC GCA CCT GCT2012Leu Phe His Gly Arg Gly Gly Ser Ile Gly Ar - #g Gly Gly Ala Pro Ala# 590- CAT GCG GCG CTG CTG TCA CAA CCG CCA GGA AG - #C CTG AAA GGC GGC CTG2060His Ala Ala Leu Leu Ser Gln Pro Pro Gly Se - #r Leu Lys Gly Gly Leu# 605- CGC GTA ACC GAA CAG GGC GAG ATG ATC CGC TT - #T AAA TAT GGT CTG CCA2108Arg Val Thr Glu Gln Gly Glu Met Ile Arg Ph - #e Lys Tyr Gly Leu Pro# 620- GAA ATC ACC GTC AGC AGC CTG TCG CTT TAT AC - #C GGG GCG ATT CTG GAA2156Glu Ile Thr Val Ser Ser Leu Ser Leu Tyr Th - #r Gly Ala Ile Leu Glu625 6 - #30 6 - #35 6 -#40- GCC AAC CTG CTG CCA CCG CCG GAG CCG AAA GA - #G AGC TGG CGT CGC ATT2204Ala Asn Leu Leu Pro Pro Pro Glu Pro Lys Gl - #u Ser Trp Arg Arg Ile# 655- ATG GAT GAA CTG TCA GTC ATC TCC TGC GAT GT - #C TAC CGC GGC TAC GTA2252Met Asp Glu Leu Ser Val Ile Ser Cys Asp Va - #l Tyr Arg Gly Tyr Val# 670- CGT GAA AAC AAA GAT TTT GTG CCT TAC TTC CG - #C TCC GCT ACG CCG GAA2300Arg Glu Asn Lys Asp Phe Val Pro Tyr Phe Ar - #g Ser Ala Thr Pro Glu# 685- CAA GAA CTG GGC AAA CTG CCG TTG GGT TCA CG - #T CCG GCG AAA CGT CGC2348Gln Glu Leu Gly Lys Leu Pro Leu Gly Ser Ar - #g Pro Ala Lys Arg Arg# 700- CCA ACC GGC GGC GTC GAG TCA CTA CGC GCC AT - #T CCG TGG ATC TTC GCC2396Pro Thr Gly Gly Val Glu Ser Leu Arg Ala Il - #e Pro Trp Ile Phe Ala705 7 - #10 7 - #15 7 -#20- TGG ACG CAA AAC CGT CTG ATG CTC CCC GCC TG - #G CTG GGT GCA GGT ACG2444Trp Thr Gln Asn Arg Leu Met Leu Pro Ala Tr - #p Leu Gly Ala Gly Thr# 735- GCG CTG CAA AAA GTG GTC GAA GAC GGC AAA CA - #G AGC GAG CTG GAG GCT2492Ala Leu Gln Lys Val Val Glu Asp Gly Lys Gl - #n Ser Glu Leu Glu Ala# 750- ATG TGC CGC GAT TGG CCA TTC TTC TCG ACG CG - #T CTC GGC ATG CTG GAG2540Met Cys Arg Asp Trp Pro Phe Phe Ser Thr Ar - #g Leu Gly Met Leu Glu# 765- ATG GTC TTC GCC AAA GCA GAC CTG TGG CTG GC - #G GAA TAC TAT GAC CAA2588Met Val Phe Ala Lys Ala Asp Leu Trp Leu Al - #a Glu Tyr Tyr Asp Gln# 780- CGC CTG GTA GAC AAA GCA CTG TGG CCG TTA GG - #T AAA GAG TTA CGC AAC2636Arg Leu Val Asp Lys Ala Leu Trp Pro Leu Gl - #y Lys Glu Leu Arg Asn785 7 - #90 7 - #95 8 -#00- CTG CAA GAA GAA GAC ATC AAA GTG GTG CTG GC - #G ATT GCC AAC GAT TCC2684Leu Gln Glu Glu Asp Ile Lys Val Val Leu Al - #a Ile Ala Asn Asp Ser# 815- CAT CTG ATG GCC GAT CTG CCG TGG ATT GCA GA - #G TCT ATT CAG CTA CGG2732His Leu Met Ala Asp Leu Pro Trp Ile Ala Gl - #u Ser Ile Gln Leu Arg# 830- AAT ATT TAC ACC GAC CCG CTG AAC GTA TTG CA - #G GCC GAG TTG CTG CAC2780Asn Ile Tyr Thr Asp Pro Leu Asn Val Leu Gl - #n Ala Glu Leu Leu His# 845- CGC TCC CGC CAG GCA GAA AAA GAA GGC CAG GA - #A CCG GAT CCT CGC GTC2828Arg Ser Arg Gln Ala Glu Lys Glu Gly Gln Gl - #u Pro Asp Pro Arg Val# 860- GAA CAA GCG TTA ATG GTC ACT ATT GCC GGG AT - #T GCG GCA GGT ATG CGT2876Glu Gln Ala Leu Met Val Thr Ile Ala Gly Il - #e Ala Ala Gly Met Arg865 8 - #70 8 - #75 8 -#80- AAT ACC GGC TAA TCTTCCTCTT CTGCAAACCC TCGTGCTTTT GC - #GCGAGGGT2928Asn Thr GlyTTTCTGAAAT ACTTCTGTTC TAACACCCTC GTTTTCAATA TATTTCTGTC TG - #CATTTTAT2988- TCAAATTCTG AATATACCTT CAGATATCCT TAAGGGCCTC GTGATACGCC TA - #TTTTTATA3048- GGTTAATGTC ATGATAATAA TGGTTTCTTA GACGTCAGGT GGCACTTTTC GG - #GGAAATGT3108- GCGCGGAACC CCTATTTGTT TATTTTTCTA AATACATTCA AATATGTATC CG - #CTCATGAG3168- ACAATAACCC TGATAAATGC TTCAATAATA TTGAAAAAGG AAGAGTATGA GT - #ATTCAACA3228- TTTCCGTGTC GCCCTTATTC CCTTTTTTGC GGCATTTTGC CTTCCTGTTT TT - #GCTCACCC3288- AGAAACGCTG GTGAAAGTAA AAGATGCTGA AGATCAGTTG GGTGCACGAG TG - #GGTTACAT3348- CGAACTGGAT CTCAACAGCG GTAAGATCCT TGAGAGTTTT CGCCCCGAAG AA - #CGTTTTCC3408- AATGATGAGC ACTTTTAAAG TTCTGCTATG TGGCGCGGTA TTATCCCGTA TT - #GACGCCGG3468- GCAAGAGCAA CTCGGTCGCC GCATACACTA TTCTCAGAAT GACTTGGTTG AG - #TACTCACC3528- AGTCACAGAA AAGCATCTTA CGGATGGCAT GACAGTAAGA GAATTATGCA GT - #GCTGCCAT3588- AACCATGAGT GATAACACTG CGGCCAACTT ACTTCTGACA ACGATCGGAG GA - #CCGAAGGA3648- GCTAACCGCT TTTTTGCACA ACATGGGGGA TCATGTAACT CGCCTTGATC GT - #TGGGAACC3708- GGAGCTGAAT GAAGCCATAC CAAACGACGA GCGTGACACC ACGATGCCTG TA - #GCAATGGC3768- AACAACGTTG CGCAAACTAT TAACTGGCGA ACTACTTACT CTAGCTTCCC GG - #CAACAATT3828- AATAGACTGG ATGGAGGCGG ATAAAGTTGC AGGACCACTT CTGCGCTCGG CC - #CTTCCGGC3888- TGGCTGGTTT ATTGCTGATA AATCTGGAGC CGGTGAGCGT GGGTCTCGCG GT - #ATCATTGC3948- AGCACTGGGG CCAGATGGTA AGCCCTCCCG TATCGTAGTT ATCTACACGA CG - #GGGAGTCA4008- GGCAACTATG GATGAACGAA ATAGACAGAT CGCTGAGATA GGTGCCTCAC TG - #ATTAAGCA4068- TTGGTAACTG TCAGACCAAG TTTACTCATA TATACTTTAG ATTGATTTAA AA - #CTTCATTT4128- TTAATTTAAA AGGATCTAGG TGAAGATCCT TTTTGATAAT CTCATGACCA AA - #ATCCCTTA4188- ACGTGAGTTT TCGTTCCACT GAGCGTCAGA CCCCGTAGAA AAGATCAAAG GA - #TCTTCTTG4248- AGATCCTTTT TTTCTGCGCG TAATCTGCTG CTTGCAAACA AAAAAACCAC CG - #CTACCAGC4308- GGTGGTTTGT TTGCCGGATC AAGAGCTACC AACTCTTTTT CCGAAGGTAA CT - #GGCTTCAG4368- CAGAGCGCAG ATACCAAATA CTGTCCTTCT AGTGTAGCCG TAGTTAGGCC AC - #CACTTCAA4428- GAACTCTGTA GCACCGCCTA CATACCTCGC TCTGCTAATC CTGTTACCAG TG - #GCTGCTGC4488- CAGTGGCGAT AAGTCGTGTC TTACCGGGTT GGACTCAAGA CGATAGTTAC CG - #GATAAGGC4548- GCAGCGGTCG GGCTGAACGG GGGGTTCGTG CACACAGCCC AGCTTGGAGC GA - #ACGACCTA4608- CACCGAACTG AGATACCTAC AGCGTGAGCA TTGAGAAAGC GCCACGCTTC CC - #GAAGGGAG4668- AAAGGCGGAC AGGTATCCGG TAAGCGGCAG GGTCGGAACA GGAGAGCGCA CG - #AGGGAGCT4728- TCCAGGGGGA AACGCCTGGT ATCTTTATAG TCCTGTCGGG TTTCGCCACC TC - #TGACTTGA4788- GCGTCGATTT TTGTGATGCT CGTCAGGGGG GCGGAGCCTA TGGAAAAACG CC - #AGCAACGC4848- GGCCTTTTTA CGGTTCCTGG CCTTTTGCTG GCCTTTTGCT CACATGTTCT TT - #CCTGCGTT4908- ATCCCCTGAT TCTGTGGATA ACCGTATTAC CGCCTTTGAG TGAGCTGATA CC - #GCTCGCCG4968- CAGCCGAACG ACCGAGCGCA GCGAGTCAGT GAGCGAGGAA GCGGAAGAGC GC - #CCAATACG5028- CAAACCGCCT CTCCCCGCGC GTTGGCCGAT TCATTAATGC AGAAGGGTTG GT - #TTGCGCAT5088- TCACAGTTCT CCGCAAGAAT TGATTGGCTC CAATTCTTGG AGTGGTGAAT CC - #GTTAGCGA5148# 5186 ATTC AGGTCGAGGT GGCCCGGG- (2) INFORMATION FOR SEQ ID NO:2:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 883 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:- Met Asn Glu Gln Tyr Ser Ala Leu Arg Ser As - #n Val Ser Met Leu Gly# 15- Lys Val Leu Gly Glu Thr Ile Lys Asp Ala Le - #u Gly Glu His Ile Leu# 30- Glu Arg Val Glu Thr Ile Arg Lys Leu Ser Ly - #s Ser Ser Arg Ala Gly# 45- Asn Asp Ala Asn Arg Gln Glu Leu Leu Thr Th - #r Leu Gln Asn Leu Ser# 60- Asn Asp Glu Leu Leu Pro Val Ala Arg Ala Ph - #e Ser Gln Phe Leu Asn# 80- Leu Ala Asn Thr Ala Glu Gln Tyr His Ser Il - #e Ser Pro Lys Gly Glu# 95- Ala Ala Ser Asn Pro Glu Val Ile Ala Arg Th - #r Leu Arg Lys Leu Lys# 110- Asn Gln Pro Glu Leu Ser Glu Asp Thr Ile Ly - #s Lys Ala Val Glu Ser# 125- Leu Ser Leu Glu Leu Val Leu Thr Ala His Pr - #o Thr Glu Ile Thr Arg# 140- Arg Thr Leu Ile His Lys Met Val Glu Val As - #n Ala Cys Leu Lys Gln145 1 - #50 1 - #55 1 -#60- Leu Asp Asn Lys Asp Ile Ala Asp Tyr Glu Hi - #s Asn Gln Leu Met Arg# 175- Arg Leu Arg Gln Leu Ile Ala Gln Ser Trp Hi - #s Thr Asp Glu Ile Arg# 190- Lys Leu Arg Pro Ser Pro Val Asp Glu Ala Ly - #s Trp Gly Phe Ala Val# 205- Val Glu Asn Ser Leu Trp Gln Gly Val Pro As - #n Tyr Leu Arg Glu Leu# 220- Asn Glu Gln Leu Glu Glu Asn Leu Gly Tyr Ly - #s Leu Pro Val Glu Phe225 2 - #30 2 - #35 2 -#40- Val Pro Val Arg Phe Thr Ser Trp Met Gly Gl - #y Asp Arg Asp Gly Asn# 255- Pro Asn Val Thr Ala Asp Ile Thr Arg His Va - #l Leu Leu Leu Ser Arg# 270- Trp Lys Ala Thr Asp Leu Phe Leu Lys Asp Il - #e Gln Val Leu Val Ser# 285- Glu Leu Ser Met Val Glu Ala Thr Pro Glu Le - #u Leu Ala Leu Val Gly# 300- Glu Glu Gly Ala Ala Glu Pro Tyr Arg Tyr Le - #u Met Lys Asn Leu Arg305 3 - #10 3 - #15 3 -#20- Ser Arg Leu Met Ala Thr Gln Ala Trp Leu Gl - #u Ala Arg Leu Lys Gly# 335- Glu Glu Leu Pro Lys Pro Glu Gly Leu Leu Th - #r Gln Asn Glu Glu Leu# 350- Trp Glu Pro Leu Tyr Ala Cys Tyr Gln Ser Le - #u Gln Ala Cys Gly Met# 365- Gly Ile Ile Ala Asn Gly Asp Leu Leu Asp Th - #r Leu Arg Arg Val Lys# 380- Cys Phe Gly Val Pro Leu Val Arg Ile Asp Il - #e Arg Gln Glu Ser Thr385 3 - #90 3 - #95 4 -#00- Arg His Thr Glu Ala Leu Gly Glu Leu Thr Ar - #g Tyr Leu Gly Ile Gly# 415- Asp Tyr Glu Ser Trp Ser Glu Ala Asp Lys Gl - #n Ala Phe Leu Ile Arg# 430- Glu Leu Asn Ser Lys Arg Pro Leu Leu Pro Ar - #g Asn Trp Gln Pro Ser# 445- Ala Glu Thr Arg Glu Val Leu Asp Thr Cys Gl - #n Val Ile Ala Glu Ala# 460- Pro Gln Gly Ser Ile Ala Ala Tyr Val Ile Se - #r Met Ala Lys Thr Pro465 4 - #70 4 - #75 4 -#80- Ser Asp Val Leu Ala Val His Leu Leu Leu Ly - #s Glu Ala Gly Ile Gly# 495- Phe Ala Met Pro Val Ala Pro Leu Phe Glu Th - #r Leu Asp Asp Leu Asn# 510- Asn Ala Asn Asp Val Met Thr Gln Leu Leu As - #n Ile Asp Trp Tyr Arg# 525- Gly Leu Ile Gln Gly Lys Gln Met Val Met Il - #e Gly Tyr Ser Asp Ser# 540- Ala Lys Asp Ala Gly Val Met Ala Ala Ser Tr - #p Ala Gln Tyr Gln Ala545 5 - #50 5 - #55 5 -#60- Gln Asp Ala Leu Ile Lys Thr Cys Glu Lys Al - #a Gly Ile Glu Leu Thr# 575- Leu Phe His Gly Arg Gly Gly Ser Ile Gly Ar - #g Gly Gly Ala Pro Ala# 590- His Ala Ala Leu Leu Ser Gln Pro Pro Gly Se - #r Leu Lys Gly Gly Leu# 605- Arg Val Thr Glu Gln Gly Glu Met Ile Arg Ph - #e Lys Tyr Gly Leu Pro# 620- Glu Ile Thr Val Ser Ser Leu Ser Leu Tyr Th - #r Gly Ala Ile Leu Glu625 6 - #30 6 - #35 6 -#40- Ala Asn Leu Leu Pro Pro Pro Glu Pro Lys Gl - #u Ser Trp Arg Arg Ile# 655- Met Asp Glu Leu Ser Val Ile Ser Cys Asp Va - #l Tyr Arg Gly Tyr Val# 670- Arg Glu Asn Lys Asp Phe Val Pro Tyr Phe Ar - #g Ser Ala Thr Pro Glu# 685- Gln Glu Leu Gly Lys Leu Pro Leu Gly Ser Ar - #g Pro Ala Lys Arg Arg# 700- Pro Thr Gly Gly Val Glu Ser Leu Arg Ala Il - #e Pro Trp Ile Phe Ala705 7 - #10 7 - #15 7 -#20- Trp Thr Gln Asn Arg Leu Met Leu Pro Ala Tr - #p Leu Gly Ala Gly Thr# 735- Ala Leu Gln Lys Val Val Glu Asp Gly Lys Gl - #n Ser Glu Leu Glu Ala# 750- Met Cys Arg Asp Trp Pro Phe Phe Ser Thr Ar - #g Leu Gly Met Leu Glu# 765- Met Val Phe Ala Lys Ala Asp Leu Trp Leu Al - #a Glu Tyr Tyr Asp Gln# 780- Arg Leu Val Asp Lys Ala Leu Trp Pro Leu Gl - #y Lys Glu Leu Arg Asn785 7 - #90 7 - #95 8 -#00- Leu Gln Glu Glu Asp Ile Lys Val Val Leu Al - #a Ile Ala Asn Asp Ser# 815- His Leu Met Ala Asp Leu Pro Trp Ile Ala Gl - #u Ser Ile Gln Leu Arg# 830- Asn Ile Tyr Thr Asp Pro Leu Asn Val Leu Gl - #n Ala Glu Leu Leu His# 845- Arg Ser Arg Gln Ala Glu Lys Glu Gly Gln Gl - #u Pro Asp Pro Arg Val# 860- Glu Gln Ala Leu Met Val Thr Ile Ala Gly Il - #e Ala Ala Gly Met Arg865 8 - #70 8 - #75 8 -#80- Asn Thr Gly- (2) INFORMATION FOR SEQ ID NO:3:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 23 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "Synthetic DNA"RIPTION: /desc- (iii) HYPOTHETICAL: NO- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:# 23GTCA CTT- (2) INFORMATION FOR SEQ ID NO:4:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 21 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "Synthetic DNA"RIPTION: /desc- (iii) HYPOTHETICAL: NO- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:#21 CGGC C- (2) INFORMATION FOR SEQ ID NO:5:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1643 base (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (vi) ORIGINAL SOURCE: (A) ORGANISM: Corynebacter - #ium glutamicum (B) STRAIN: ATCC13869- (ix) FEATURE: (A) NAME/KEY: mat.sub.-- - #peptide (B) LOCATION: 217..1482- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:- TCGCGAAGTA GCACCTGTCA CTTTTGTCTC AAATATTAAA TCGAATATCA AT - #ATACGGTC 60- TGTTTATTGG AACGCATCCC AGTGGCTGAG ACGCATCCGC TAAAGCCCCA GG - #AACCCTGT 120- GCAGAAAGAA AACACTCCTC TGGCTAGGTA GACACAGTTT ATAAAGGTAG AG - #TTGAGCGG 180#GTC GTA CAG 234AT CGAAAGGTGC ACAAAG GTG GCC CTG# Met Ala Leu Val Val Gln# 5 1- AAA TAT GGC GGT TCC TCG CTT GAG AGT GCG GA - #A CGC ATT AGA AAC GTC 282Lys Tyr Gly Gly Ser Ser Leu Glu Ser Ala Gl - #u Arg Ile Arg Asn Val# 20- GCT GAA CGG ATC GTT GCC ACC AAG AAG GCT GG - #A AAT GAT GTC GTG GTT 330Ala Glu Arg Ile Val Ala Thr Lys Lys Ala Gl - #y Asn Asp Val Val Val# 35- GTC TGC TCC GCA ATG GGA GAC ACC ACG GAT GA - #A CTT CTA GAA CTT GCA 378Val Cys Ser Ala Met Gly Asp Thr Thr Asp Gl - #u Leu Leu Glu Leu Ala# 50- GCG GCA GTG AAT CCC GTT CCG CCA GCT CGT GA - #A ATG GAT ATG CTC CTG 426Ala Ala Val Asn Pro Val Pro Pro Ala Arg Gl - #u Met Asp Met Leu Leu# 70- ACT GCT GGT GAG CGT ATT TCT AAC GCT CTC GT - #C GCC ATG GCT ATT GAG 474Thr Ala Gly Glu Arg Ile Ser Asn Ala Leu Va - #l Ala Met Ala Ile Glu# 85- TCC CTT GGC GCA GAA GCT CAA TCT TTC ACT GG - #C TCT CAG GCT GGT GTG 522Ser Leu Gly Ala Glu Ala Gln Ser Phe Thr Gl - #y Ser Gln Ala Gly Val# 100- CTC ACC ACC GAG CGC CAC GGA AAC GCA CGC AT - #T GTT GAC GTC ACA CCG 570Leu Thr Thr Glu Arg His Gly Asn Ala Arg Il - #e Val Asp Val Thr Pro# 115- GGT CGT GTG CGT GAA GCA CTC GAT GAG GGC AA - #G ATC TGC ATT GTT GCT 618Gly Arg Val Arg Glu Ala Leu Asp Glu Gly Ly - #s Ile Cys Ile Val Ala# 130- GGT TTT CAG GGT GTT AAT AAA GAA ACC CGC GA - #T GTC ACC ACG TTG GGT 666Gly Phe Gln Gly Val Asn Lys Glu Thr Arg As - #p Val Thr Thr Leu Gly135 1 - #40 1 - #45 1 -#50- CGT GGT GGT TCT GAC ACC ACT GCA GTT GCG TT - #G GCA GCT GCT TTG AAC 714Arg Gly Gly Ser Asp Thr Thr Ala Val Ala Le - #u Ala Ala Ala Leu Asn# 165- GCT GAT GTG TGT GAG ATT TAC TCG GAC GTT GA - #C GGT GTG TAT ACC GCT 762Ala Asp Val Cys Glu Ile Tyr Ser Asp Val As - #p Gly Val Tyr Thr Ala# 180- GAC CCG CGC ATC GTT CCT AAT GCA CAG AAG CT - #G GAA AAG CTC AGC TTC 810Asp Pro Arg Ile Val Pro Asn Ala Gln Lys Le - #u Glu Lys Leu Ser Phe# 195- GAA GAA ATG CTG GAA CTT GCT GCT GTT GGC TC - #C AAG ATT TTG GTG CTG 858Glu Glu Met Leu Glu Leu Ala Ala Val Gly Se - #r Lys Ile Leu Val Leu# 210- CGC AGT GTT GAA TAC GCT CGT GCA TTC AAT GT - #G CCA CTT CGC GTA CGC 906Arg Ser Val Glu Tyr Ala Arg Ala Phe Asn Va - #l Pro Leu Arg Val Arg215 2 - #20 2 - #25 2 -#30- TCG TCT TAT AGT AAT GAT CCC GGC ACT TTG AT - #T GCC GGC TCT ATG GAG 954Ser Ser Tyr Ser Asn Asp Pro Gly Thr Leu Il - #e Ala Gly Ser Met Glu# 245- GAT ATT CCT GTG GAA GAA GCA GTC CTT ACC GG - #T GTC GCA ACC GAC AAG1002Asp Ile Pro Val Glu Glu Ala Val Leu Thr Gl - #y Val Ala Thr Asp Lys# 260- TCC GAA GCC AAA GTA ACC GTT CTG GGT ATT TC - #C GAT AAG CCA GGC GAG1050Ser Glu Ala Lys Val Thr Val Leu Gly Ile Se - #r Asp Lys Pro Gly Glu# 275- GCT GCC AAG GTT TTC CGT GCG TTG GCT GAT GC - #A GAA ATC AAC ATT GAC1098Ala Ala Lys Val Phe Arg Ala Leu Ala Asp Al - #a Glu Ile Asn Ile Asp# 290- ATG GTT CTG CAG AAC GTC TCC TCT GTG GAA GA - #C GGC ACC ACC GAC ATC1146Met Val Leu Gln Asn Val Ser Ser Val Glu As - #p Gly Thr Thr Asp Ile295 3 - #00 3 - #05 3 -#10- ACG TTC ACC TGC CCT CGC GCT GAC GGA CGC CG - #T GCG ATG GAG ATC TTG1194Thr Phe Thr Cys Pro Arg Ala Asp Gly Arg Ar - #g Ala Met Glu Ile Leu# 325- AAG AAG CTT CAG GTT CAG GGC AAC TGG ACC AA - #T GTG CTT TAC GAC GAC1242Lys Lys Leu Gln Val Gln Gly Asn Trp Thr As - #n Val Leu Tyr Asp Asp# 340- CAG GTC GGC AAA GTC TCC CTC GTG GGT GCT GG - #C ATG AAG TCT CAC CCA1290Gln Val Gly Lys Val Ser Leu Val Gly Ala Gl - #y Met Lys Ser His Pro# 355- GGT GTT ACC GCA GAG TTC ATG GAA GCT CTG CG - #C GAT GTC AAC GTG AAC1338Gly Val Thr Ala Glu Phe Met Glu Ala Leu Ar - #g Asp Val Asn Val Asn# 370- ATC GAA TTG ATT TCC ACC TCT GAG ATC CGC AT - #T TCC GTG CTG ATC CGT1386Ile Glu Leu Ile Ser Thr Ser Glu Ile Arg Il - #e Ser Val Leu Ile Arg375 3 - #80 3 - #85 3 -#90- GAA GAT GAT CTG GAT GCT GCT GCA CGT GCA TT - #G CAT GAG CAG TTC CAG1434Glu Asp Asp Leu Asp Ala Ala Ala Arg Ala Le - #u His Glu Gln Phe Gln# 405- CTG GGC GGC GAA GAC GAA GCC GTC GTT TAT GC - #A GGC ACC GGA CGC TAA1482Leu Gly Gly Glu Asp Glu Ala Val Val Tyr Al - #a Gly Thr Gly Arg# 420- AGTTTTAAAG GAGTAGTTTT ACAATGACCA CCATCGCAGT TGTTGGTGCA AC - #CGGCCAGG1542- TCGGCCAGGT TATGCGCACC CTTTTGGAAG AGCGCAATTT CCCAGCTGAC AC - #TGTTCGTT1602# 1643 TTCC GCAGGCCGTA AGATTGAATT C- (2) INFORMATION FOR SEQ ID NO:6:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 421 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:- Met Ala Leu Val Val Gln Lys Tyr Gly Gly Se - #r Ser Leu Glu Ser Ala# 15- Glu Arg Ile Arg Asn Val Ala Glu Arg Ile Va - #l Ala Thr Lys Lys Ala# 30- Gly Asn Asp Val Val Val Val Cys Ser Ala Me - #t Gly Asp Thr Thr Asp# 45- Glu Leu Leu Glu Leu Ala Ala Ala Val Asn Pr - #o Val Pro Pro Ala Arg# 60- Glu Met Asp Met Leu Leu Thr Ala Gly Glu Ar - #g Ile Ser Asn Ala Leu# 80- Val Ala Met Ala Ile Glu Ser Leu Gly Ala Gl - #u Ala Gln Ser Phe Thr# 95- Gly Ser Gln Ala Gly Val Leu Thr Thr Glu Ar - #g His Gly Asn Ala Arg# 110- Ile Val Asp Val Thr Pro Gly Arg Val Arg Gl - #u Ala Leu Asp Glu Gly# 125- Lys Ile Cys Ile Val Ala Gly Phe Gln Gly Va - #l Asn Lys Glu Thr Arg# 140- Asp Val Thr Thr Leu Gly Arg Gly Gly Ser As - #p Thr Thr Ala Val Ala145 1 - #50 1 - #55 1 -#60- Leu Ala Ala Ala Leu Asn Ala Asp Val Cys Gl - #u Ile Tyr Ser Asp Val# 175- Asp Gly Val Tyr Thr Ala Asp Pro Arg Ile Va - #l Pro Asn Ala Gln Lys# 190- Leu Glu Lys Leu Ser Phe Glu Glu Met Leu Gl - #u Leu Ala Ala Val Gly# 205- Ser Lys Ile Leu Val Leu Arg Ser Val Glu Ty - #r Ala Arg Ala Phe Asn# 220- Val Pro Leu Arg Val Arg Ser Ser Tyr Ser As - #n Asp Pro Gly Thr Leu225 2 - #30 2 - #35 2 -#40- Ile Ala Gly Ser Met Glu Asp Ile Pro Val Gl - #u Glu Ala Val Leu Thr# 255- Gly Val Ala Thr Asp Lys Ser Glu Ala Lys Va - #l Thr Val Leu Gly Ile# 270- Ser Asp Lys Pro Gly Glu Ala Ala Lys Val Ph - #e Arg Ala Leu Ala Asp# 285- Ala Glu Ile Asn Ile Asp Met Val Leu Gln As - #n Val Ser Ser Val Glu# 300- Asp Gly Thr Thr Asp Ile Thr Phe Thr Cys Pr - #o Arg Ala Asp Gly Arg305 3 - #10 3 - #15 3 -#20- Arg Ala Met Glu Ile Leu Lys Lys Leu Gln Va - #l Gln Gly Asn Trp Thr# 335- Asn Val Leu Tyr Asp Asp Gln Val Gly Lys Va - #l Ser Leu Val Gly Ala# 350- Gly Met Lys Ser His Pro Gly Val Thr Ala Gl - #u Phe Met Glu Ala Leu# 365- Arg Asp Val Asn Val Asn Ile Glu Leu Ile Se - #r Thr Ser Glu Ile Arg# 380- Ile Ser Val Leu Ile Arg Glu Asp Asp Leu As - #p Ala Ala Ala Arg Ala385 3 - #90 3 - #95 4 -#00- Leu His Glu Gln Phe Gln Leu Gly Gly Glu As - #p Glu Ala Val Val Tyr# 415- Ala Gly Thr Gly Arg 420- (2) INFORMATION FOR SEQ ID NO:7:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 1643 base (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: DNA (genomic)- (vi) ORIGINAL SOURCE: (A) ORGANISM: Corynebacter - #ium glutamicum (B) STRAIN: ATCC13869- (ix) FEATURE: (A) NAME/KEY: mat.sub.-- - #peptide (B) LOCATION: 964..1482- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:- TCGCGAAGTA GCACCTGTCA CTTTTGTCTC AAATATTAAA TCGAATATCA AT - #ATACGGTC 60- TGTTTATTGG AACGCATCCC AGTGGCTGAG ACGCATCCGC TAAAGCCCCA GG - #AACCCTGT 120- GCAGAAAGAA AACACTCCTC TGGCTAGGTA GACACAGTTT ATAAAGGTAG AG - #TTGAGCGG 180- GTAACTGTCA GCACGTAGAT CGAAAGGTGC ACAAAGGTGG CCCTGGTCGT AC - #AGAAATAT 240- GGCGGTTCCT CGCTTGAGAG TGCGGAACGC ATTAGAAACG TCGCTGAACG GA - #TCGTTGCC 300- ACCAAGAAGG CTGGAAATGA TGTCGTGGTT GTCTGCTCCG CAATGGGAGA CA - #CCACGGAT 360- GAACTTCTAG AACTTGCAGC GGCAGTGAAT CCCGTTCCGC CAGCTCGTGA AA - #TGGATATG 420- CTCCTGACTG CTGGTGAGCG TATTTCTAAC GCTCTCGTCG CCATGGCTAT TG - #AGTCCCTT 480- GGCGCAGAAG CTCAATCTTT CACTGGCTCT CAGGCTGGTG TGCTCACCAC CG - #AGCGCCAC 540- GGAAACGCAC GCATTGTTGA CGTCACACCG GGTCGTGTGC GTGAAGCACT CG - #ATGAGGGC 600- AAGATCTGCA TTGTTGCTGG TTTTCAGGGT GTTAATAAAG AAACCCGCGA TG - #TCACCACG 660- TTGGGTCGTG GTGGTTCTGA CACCACTGCA GTTGCGTTGG CAGCTGCTTT GA - #ACGCTGAT 720- GTGTGTGAGA TTTACTCGGA CGTTGACGGT GTGTATACCG CTGACCCGCG CA - #TCGTTCCT 780- AATGCACAGA AGCTGGAAAA GCTCAGCTTC GAAGAAATGC TGGAACTTGC TG - #CTGTTGGC 840- TCCAAGATTT TGGTGCTGCG CAGTGTTGAA TACGCTCGTG CATTCAATGT GC - #CACTTCGC 900- GTACGCTCGT CTTATAGTAA TGATCCCGGC ACTTTGATTG CCGGCTCTAT GG - #AGGATATT 960- CCT GTG GAA GAA GCA GTC CTT ACC GGT GTC GC - #A ACC GAC AAG TCC GAA1008#Val Ala Thr Asp Lys Ser GluThr Gly# 15- GCC AAA GTA ACC GTT CTG GGT ATT TCC GAT AA - #G CCA GGC GAG GCT GCC1056Ala Lys Val Thr Val Leu Gly Ile Ser Asp Ly - #s Pro Gly Glu Ala Ala# 30- AAG GTT TTC CGT GCG TTG GCT GAT GCA GAA AT - #C AAC ATT GAC ATG GTT1104Lys Val Phe Arg Ala Leu Ala Asp Ala Glu Il - #e Asn Ile Asp Met Val# 45- CTG CAG AAC GTC TCC TCT GTG GAA GAC GGC AC - #C ACC GAC ATC ACG TTC1152Leu Gln Asn Val Ser Ser Val Glu Asp Gly Th - #r Thr Asp Ile Thr Phe# 60- ACC TGC CCT CGC GCT GAC GGA CGC CGT GCG AT - #G GAG ATC TTG AAG AAG1200Thr Cys Pro Arg Ala Asp Gly Arg Arg Ala Me - #t Glu Ile Leu Lys Lys# 75- CTT CAG GTT CAG GGC AAC TGG ACC AAT GTG CT - #T TAC GAC GAC CAG GTC1248Leu Gln Val Gln Gly Asn Trp Thr Asn Val Le - #u Tyr Asp Asp Gln Val# 95- GGC AAA GTC TCC CTC GTG GGT GCT GGC ATG AA - #G TCT CAC CCA GGT GTT1296Gly Lys Val Ser Leu Val Gly Ala Gly Met Ly - #s Ser His Pro Gly Val# 110- ACC GCA GAG TTC ATG GAA GCT CTG CGC GAT GT - #C AAC GTG AAC ATC GAA1344Thr Ala Glu Phe Met Glu Ala Leu Arg Asp Va - #l Asn Val Asn Ile Glu# 125- TTG ATT TCC ACC TCT GAG ATC CGC ATT TCC GT - #G CTG ATC CGT GAA GAT1392Leu Ile Ser Thr Ser Glu Ile Arg Ile Ser Va - #l Leu Ile Arg Glu Asp# 140- GAT CTG GAT GCT GCT GCA CGT GCA TTG CAT GA - #G CAG TTC CAG CTG GGC1440Asp Leu Asp Ala Ala Ala Arg Ala Leu His Gl - #u Gln Phe Gln Leu Gly# 155- GGC GAA GAC GAA GCC GTC GTT TAT GCA GGC AC - #C GGA CGC TAA#1482Gly Glu Asp Glu Ala Val Val Tyr Ala Gly Th - #r Gly Arg160 1 - #65 1 - #70- AGTTTTAAAG GAGTAGTTTT ACAATGACCA CCATCGCAGT TGTTGGTGCA AC - #CGGCCAGG1542- TCGGCCAGGT TATGCGCACC CTTTTGGAAG AGCGCAATTT CCCAGCTGAC AC - #TGTTCGTT1602# 1643 TTCC GCAGGCCGTA AGATTGAATT C- (2) INFORMATION FOR SEQ ID NO:8:- (i) SEQUENCE CHARACTERISTICS:#acids (A) LENGTH: 172 amino (B) TYPE: amino acid (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: protein- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:- Val Glu Glu Ala Val Leu Thr Gly Val Ala Th - #r Asp Lys Ser Glu Ala# 15- Lys Val Thr Val Leu Gly Ile Ser Asp Lys Pr - #o Gly Glu Ala Ala Lys# 30- Val Phe Arg Ala Leu Ala Asp Ala Glu Ile As - #n Ile Asp Met Val Leu# 45- Gln Asn Val Ser Ser Val Glu Asp Gly Thr Th - #r Asp Ile Thr Phe Thr# 60- Cys Pro Arg Ala Asp Gly Arg Arg Ala Met Gl - #u Ile Leu Lys Lys Leu# 80- Gln Val Gln Gly Asn Trp Thr Asn Val Leu Ty - #r Asp Asp Gln Val Gly# 95- Lys Val Ser Leu Val Gly Ala Gly Met Lys Se - #r His Pro Gly Val Thr# 110- Ala Glu Phe Met Glu Ala Leu Arg Asp Val As - #n Val Asn Ile Glu Leu# 125- Ile Ser Thr Ser Glu Ile Arg Ile Ser Val Le - #u Ile Arg Glu Asp Asp# 140- Leu Asp Ala Ala Ala Arg Ala Leu His Glu Gl - #n Phe Gln Leu Gly Gly145 1 - #50 1 - #55 1 -#60- Glu Asp Glu Ala Val Val Tyr Ala Gly Thr Gl - #y Arg# 170- (2) INFORMATION FOR SEQ ID NO:9:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 16 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "Synthetic DNA"RIPTION: /desc- (iii) HYPOTHETICAL: NO- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:# 16- (2) INFORMATION FOR SEQ ID NO:10:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 20 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "Synthetic DNA"RIPTION: /desc- (iii) HYPOTHETICAL: NO- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:# 20 GGCC- (2) INFORMATION FOR SEQ ID NO:11:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 20 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "Synthetic DNA"RIPTION: /desc- (iii) HYPOTHETICAL: NO- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:# 20 CCGC- (2) INFORMATION FOR SEQ ID NO:12:- (i) SEQUENCE CHARACTERISTICS:#pairs (A) LENGTH: 15 base (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear- (ii) MOLECULE TYPE: other nucleic acid#= "Synthetic DNA"RIPTION: /desc- (iii) HYPOTHETICAL: NO- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:# 15__________________________________________________________________________

Claims

1. An isolated DNA fragment which codes for a mutant phosphoenolpyruvate carboxylase of SEQ ID NO:2, wherein said mutant phosphoenolpyuvate carboxylate has a mutation to desensitize feedback inhibition of the phosphoenolpyruvate carboxylase by aspartic acid,

wherein said mutation is at least one selected from the group consisting of:

(i) mutation of the glutamic acid residue at the 625th position of SEQ ID NO:2 to an amino acid residue other than glutamic acid;

(ii) mutation of the arginine residue at the 222nd position of SEQ ID NO:2 and the glutamic acid residue at the 223rd position of SEQ ID NO:2 to an amino acid residue other than arginine and an amino acid residue other than glutamic acid, respectively;

(iii) mutation of the serine residue at the 288th position of SEQ ID NO:2, the glutamic acid residue at the 289th position of SEQ ID NO:2, the methionine residue at the 551st position of SEQ ID NO:2 and the glutamic acid residue at the 804th position of SEQ ID NO:2 to an amino acid residue other than serine, an amino acid residue other than glutamic acid, an amino acid residue other than methionine and an amino acid residue other than glutamic acid, respectively;

(iv) mutation of the alanine residue at the 867th position of SEQ ID NO:2 to an amino acid residue other than alanine;

(v) mutation of the arginine residue at the 438th position of SEQ ID NO:2 to an amino acid residue other than arginine; and

(vi) mutation of the lysine residue at the 620th position of SEQ ID NO:2 to an amino acid residue other than lysine, and

each of said positions is a position from the N-terminus of said mutant phsphoenolpyruvate carboxylase.

2. A microorganism belonging to the genus Escherichia or coryneform bacteria, transformed by integration of the DNA fragment as defined in claim 1 into the chromosomal DNA of said microorganism.

3. A recombinant DNA formed by ligating the DNA fragment as defined in claim 1 with a vector DNA capable of autonomously replication in cells of bacteria belonging to the genus Escherichia or coryneform bacteria.

4. A microorganism belonging to the genus Escherichia or coryneform bacteria, transformed with the recombinant DNA as defined in claim 3.

5. The DNA fragment according to claim 1 wherein said mutation is at least one selected from the group consisting of:

(i) mutation of the glutamic acid residue at the 625th position of SEQ ID NO:2 to a lysine residue;

(ii) mutation of the arginine residue at the 222nd position of SEQ ID NO:2 and the glutamic acid residue at the 223rd position of SEQ ID NO:2 to a histidine residue and a lysine residue, respectively;

(iii) mutation of the serine residue at the 288th position of SEQ ID NO:2, the glutamic acid residue at the 289th postion of SEQ ID NO:2, the methionine residue at the 551st position of SEQ ID NO:2 and the glutamic acid residue at the 804th position of SEQ ID NO:2 to a phenylalanine residue, a lysine residue, an isoleucine residue and a lysine residue, respectively;

(iv) mutation of the alanine residue at the 867th position of SEQ ID NO:2 to a threonine residue;

(v) mutation of the arginine residue at the 438th position of SEQ ID NO:2 to a cysteine residue; and

(vi) mutation of the lysine residue at the 620th position of SEQ ID NO:2 to a serine residue.

6. The DNA fragment according to claim 5, wherein said mutation is mutation of the glutamic acid residue at the 625th position of SEQ ID NO:2 to a lysine residue.

7. The DNA fragment according to claim 5, wherein said mutation is mutation of the arginine residue at the 222th position of SEQ ID NO:2 and the glutamic acid residue at the 223rd position of SEQ ID NO:2 to a histidine residue and a lysine residue respectively.

8. The DNA fragment according to claim 5, wherein said mutation is mutation of the serine residue at the 288th position of SEQ ID NO:2, the glutamic acid residue at the 289th position of SEQ ID NO:2, the methionine residue at the 551st position of SEQ ID NO:2 and the glutamic acid residue at the 804th position of SEQ ID NO:2 to a phenylalanine residue, a lysine residue, an isoleucine residue and a lysine residue, respectively.

9. The DNA fragment according to claim 5, wherein said mutation is mutation of the alanine residue at the 867th position of SEQ ID NO:2 to a threonine residue.

10. The DNA fragment according to claim 5, wherein said mutation is mutation of the lysine residue at the 438th position of SEQ ID NO:2 to a cysteine residue.

11. The DNA fragment according to claim 5, wherein said mutation is mutation of the lysine residue at the 620th position of SEQ ID NO:2 to a serine residue.

12. The DNA fragment according to claim 5, wherein said mutation is mutation of the glutamic acid residue at the 625th position of SEQ ID NO:2 to an amino acid residue other than glutamic acid.

13. The DNA fragment according to claim 5, wherein said mutation is mutation of the arginine residue at the 222nd position of SEQ ID NO:2 and the glutamic acid residue at the 223rd position of SEQ ID NO:2 to an amino acid residue other than arginine and an amino acid residue other than glutamic acid respectively.

14. The DNA fragment according to claim 5, wherein said mutation is mutation of the serine residue at the 288th position of SEQ ID NO:2, the glutamic acid residue at the 289th position of SEQ ID NO:2, the methionine residue at the 551st position of SEQ ID NO:2 and the glutamic acid residue at the 804th position of SEQ ID NO:2 to an amino acid residue other than serine, an amino acid residue other than glutamic acid an amino acid residue other than methionine and an amino acid residue other than glutamic acid, respectively.

15. The DNA fragment according to claim 5, wherein said mutation is mutation of the alanine residue at the 867th position of SEQ ID NO:2 to an amino acid residue other than alanine.

16. The DNA fragment according to claim 5, wherein said mutation is mutation of the arginine residue at the 438th position of SEQ ID NO:2 to an amino acid residue other than arginine.

17. The DNA fragment according to claim 5, wherein said mutation is mutation of the lysine residue at the 620th position of SEQ ID NO:2 to an amino acid residue other than lysine.